Tetrahydroquinoxalines acting as bradykinin antagonists

Abstract

The invention relates to novel tetrahydroquinoxalines and processes for their preparation, their use for the treatment and/or the prophylaxis of diseases, in particular for the treatment and/or prophylaxis of states of pain.

Description

[0001] The invention relates to novel tetrahydroquinoxalines and processes for their preparation, their use for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of states of pain.

[0002] Kinins are peptides which are produced in the plasma (bradykinin) and peripheral tissue (kallidin) owing to injuries, inflammations, asthma and in anaphylactic and endotoxic shock. In addition to the important role played by kinins in cardiovascular homeostasis or the contraction and relaxation of smooth muscles (Bhoola al. Pharmacol. Rev. 1992, 44, 1-80), they result in particular in pain, inflammation and hyperalgesia. Since they in turn promote the production of other pain mediators such as prostaglandins, tachykinins and interleukins, there is a further potentiation of the pain response.

[0003] Kinins act via two Gq/11 protein-coupled 7 transmembrane receptor subtypes; whereas the bradykinin 2 receptor (B2-R) is activated by bradykinin and kallidin, the main fragments thereof, des-Arg9-bradykinin and des-Arg10-kallidin, are the preferred agonists for the bradykinin 1 receptor (B1-R). Receptor activation leads firstly to stimulation of phospholipase C and thus to release of intracellular calcium ions, secondly to activation of phospholipase A2 which opens ion channels by protein kinase C and thus brings about depolarization and excitation of the cell (Textbook of Pain, 4th edition; Wall and Melzack, Editors; Edinburgh, 1999, pages 61-62).

[0004] B1-R is, in contrast to B2-R, downregulated under physiological conditions, and is expressed and upregulated in cells through stimulation of disease-related mediators, e.g. interleukins. It therefore makes a contribution in particular to the chronic phase of the inflammatory response and to maintaining persistent hyperalgesia. In addition, B1-R is involved in central sensitization (Pesquero et al. Proc. Nat. Acad. Sci. USA, 2000, 97, 8140-8145) and in the modulation of spinal plasticity (Wotherspoon, G. and J. Winter Neurosci. Lett. 2000, 294, 175-178).

[0005] It is therefore sensible to use B1-R antagonists for the treatment of patients with inflammatory pain, neuropathic pain and (lower) back pain, pain associated with osteoarthritis, and pain associated with another etiology.

[0006] B1-R antagonists are also suitable for the treatment of asthma, diabetic vasculopathy, rhinitis, septic shock, atherosclerosis, multiple sclerosis or rheumatoid arthritis.

[0007] 2-[3-Oxo-1-(phenylsulfonyl)-1,2,3,4-tetrahydro-2-quinoxalinyl]-N-phenylacetamide is disclosed in CAPLUS 1973, 136227, without stating a technical effect.

[0008] EP-A-0 509 398 and WO 00/00478 describe tetrahydroquinoxalines as HIV reverse transcriptase inhibitors for the treatment of viral diseases.

[0009] DE-A43 41 663 discloses tetrahydroquinoxalines as endothelin receptor antagonists for the treatment of, inter alia, migraine.

[0010] The present invention relates to compounds of the general formulae (I) and (Ia) 1

[0011] in which

[0012] A is (C1-C6)-alkanediyl,

[0013] E is a bond or (C1-C6)-alkanediyl,

[0014] Y is CO or SO2,

[0015] R1, R2, R3 and R4 are identical or different and are hydrogen, halogen, trifluoromethyl, trifluoromethoxy, hydroxyl, nitro, cyano, amino, (C1-C6)-alkyl, (C1-C6)-alkoxy, (C1-C6)-alkylthio, mono- or di-(C1-C6)-alkylamino, (C1-C6)-acyl, (C1-C6)-acyloxy, (C1-C6)-acylamino, (C1-C6)-alkoxycarbonyl, mono- or di-(C1-C6)-alkylaminocarbonyl, carbamoyl or carboxyl,

[0016] R5 is (C6-C10)-aryl or 5- to 10-membered heteroaryl, where aryl and heteroaryl are optionally substituted identically or differently by radicals selected from the group of halogen, trifluoromethyl, trifluoromethoxy, hydroxyl, nitro, cyano, amino, (C1-C6)-alkyl, (C1-C6)-alkoxy, phenoxy, (C1-C6)-alkylthio, mono- or di-(C1-C6)-alkylamino, (C1-C6)-acyl, (C1-C6)-acyloxy, (C1-C6)-acylamino, (C1-C6)-alkoxycarbonyl, mono- or di-(C1-C6)-alkylaminocarbonyl, carbamoyl, carboxyl, phenyl, 5- to 6-membered heteroaryl, propane-1,3-diyl, butane-1,4-diyl, 1,3-dioxapropane-1,3-diyl or 1,4-dioxabutane-1,4-diyl,

[0017] in which phenoxy, phenyl and 5- to 6-membered heteroaryl are in turn optionally substituted identically or differently by trifluoromethyl, (C1-C6)-alkyl, (C1-C6)-alkoxy or halogen,

[0018] R6 and R7 are identical or different and are hydrogen, (C6-C10)-aryl, 5- to 10-membered heteroaryl, 3- to 12-membered carbocyclyl, 4- to 12-membered heterocyclyl, or

[0019] are (C1-C10)-alkyl which is optionally substituted by halogen or a radical selected from the group of (C1-C6)-alkoxy, (C6-C10)-aryl, 5- to 10-membered heteroaryl, 3- to 12-membered carbocyclyl and 4- to 12-membered heterocyclyl,

[0020] where aryl, heteroaryl, heterocyclyl and carbocyclyl are optionally substituted identically or differently by radicals selected from the group of halogen, trifluoromethyl, trifluoromethoxy, hydroxyl, nitro, cyano, amino, (C1-C6)-alkyl, (C3-C8)-cycloalkyl, 5- to 7-membered heterocyclyl, (C1-C6)-alkoxy, phenoxy, (C1-C6)-alkylthio, mono- or di-(C1-C6)-alkylamino, (C1-C6)-acyl, (C1-C6)-acyloxy, (C1-C6)-acylamino, (C1-C6)-alkoxycarbonyl, mono- or di-(C1-C6)-alkylaminocarbonyl, carbamoyl, carboxyl, phenyl, 5- to 6-membered heteroaryl, propane-1,3-diyl, butane-1,4-diyl, 1,3-dioxapropane-1,3-diyl or 1,4-dioxabutane-1,4-diyl,

[0021] or

[0022] R6 and R7 together with the nitrogen atom form a 4- to 12-membered heterocyclyl radical which is bonded via nitrogen and which is optionally substituted identically or differently by radicals selected from the group of halogen, trifluoromethyl, trifluoromethoxy, hydroxyl, nitro, cyano, amino, (C1-C6)-alkyl, (C1-C6)-alkoxy, mono- or di-(C1-C6)-alkylamino, (C1-C6)-acyloxy, (C1-C6)-acyl, (C1-C6)-acylamino, (C1-C6)-alkoxycarbonyl, mono- or di-(C1-C6)-alkylaminocarbonyl, carbamoyl, carboxyl, (C3-C8)-cycloalkyl and phenyl,

[0023] where alkyl, cycloalkyl and phenyl in turn are optionally substituted identically or differently by one to three radicals selected from the group of halogen, phenyl, (C1-C6)-alkyl, (C1-C6)-alkoxy and (C1-C6)-alkylthio, in which phenyl in turn is optionally substituted identically or differently by radicals selected from the group of halogen or methyl,

[0024] R8 is hydrogen or (C1-C3)-alkyl which is optionally substituted by fluorine,

[0025] R9 is hydrogen or (C1-C6)-alkyl,

[0026] and the salts, hydrates and/or solvates thereof,

[0027] with the exception of 2-[3-oxo-1-(phenylsulfonyl)-1,2,3,4-tetrahydro-2-quinoxalinyl]-N-phenylacetamide.

[0028] The compounds of the invention may exist in stereoisomeric forms which either are related as image and mirror image (enantiomers) or which are not related as image and mirror image (diastereomers). The invention relates both to the enantiomers or diastereomers or respective mixtures thereof. These mixtures of enantiomers and diastereomers can be separated into the stereoisomerically pure constituents in a known mariner.

[0029] Salts preferred for the purposes of the invention are physiologically acceptable salts of the compounds of the invention.

[0030] Physiologically acceptable salts of the compounds of the invention may be acid addition salts of the compounds with mineral acids, carboxylic acids or sulfonic acids. Particularly preferred examples are salts with hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, ethanesulfonic acid, toluenesulfonic acid, benzenesulfonic acid, naphthalenedisulfonic acid, acetic acid, propionic acid, lactic acid, tartaric acid, citric acid, fumaric acid, maleic acid or benzoic acid.

[0031] Salts which may also be mentioned, however, are salts with conventional bases such as, for example, alkali metal salts (e.g. sodium or potassium salts), alkaline earth metal salts (e.g. calcium or magnesium salts) or ammonium salts derived from ammonia or organic amines such as, for example, diethylamine, triethylamine, ethyldiisopropylamine, procaine, dibenzylamine, N-methylmorpholine, dihydroabietylamine, 1-ephenamine or methylpiperidine.

[0032] Hydrates of the compounds of the invention are stoichiometric compositions of the compounds or its salts with water.

[0033] Solvates of the compounds of the invention are stoichiometric compositions of the compounds or its salts with solvent.

[0034] (C1-C6)-Acyl represents for the purposes of the invention a straight-chain or branched acyl radical having 1 to 6, preferably 1 to 4, carbon atoms. Preferred examples which may be mentioned are: acetyl, ethylcarbonyl, propylcarbonyl, isopropylcarbonyl, butylcarbonyl, isobutylcarbonyl, pentylcarbonyl and hexylcarbonyl. Acetyl and ethylcarbonyl are particularly preferred.

[0035] (C1-C6)-Acyloxy represents for the purposes of the invention a straight-chain or branched acyl radical having 1 to 6, preferably 1 to 4, carbon atoms which is bonded via an oxygen atom. Preferred examples which may be mentioned are: acetyloxy, ethylcarbonyloxy, propylcarbonyloxy, isopropylcarbonyloxy, butylcarbonyloxy, isobutylcarbonyloxy, pentylcarbonyloxy and hexylcarbonyloxy. Acetyloxy and ethylcarbonyloxy are particularly preferred.

[0036] (C1-C6)-Acylamino represents for the purposes of the invention a straight-chain or branched acyl radical having 1 to 6, preferably 1 to 4, carbon atoms which is bonded via a nitrogen atom. Preferred examples which may be mentioned are: acetylamino, ethylcarbonylamino, propylcarbonylamino, isopropylcarbonylamino, butylcarbonylamino, isobutylcarbonylamino, pentylcarbonylamino and hexylcarbonylamino. Acetylamino and ethylcarbonylamino are particularly preferred.

[0037] (C1-C6)-Alkanediyl represents for the purposes of the invention a straight-chain or branched alkanediyl radical having 1 to 6, preferably 1 to 4, carbon atoms. Preferred examples which may be mentioned are methylene, ethylene, ethane-1,1-diyl, propylene, propane-1,2-diyl, propane-2,2-diyl. Methylene is preferred.

[0038] (C1-C6)-Alkoxy represents a straight-chain or branched alkoxy radical having 1 to 6, preferably 1 to 4, carbon atoms. Preferred examples which may be mentioned are: methoxy, ethoxy, n-propoxy, isopropoxy, tert-butoxy, n-pentoxy and n-hexoxy.

[0039] (C1-C6)-Alkoxycarbonyl represents a straight-chain or branched alkoxycarbonyl radical having 1 to 6, preferably 1 to 4, carbon atoms. Preferred examples which may be mentioned are: methoxycarbonyl, ethoxycarbonyl, n-propoxycarbonyl, isopropoxycarbonyl and tert-butoxycarbonyl.

[0040] (C1-C10)-, (C1-C6)- and (C1-C3)-Alkyl represent a straight-chain or branched alkyl radical having, respectively, 1 to 10, 1 to 6 and 1 to 3 carbon atoms. Preference is given in the case of (C1-C10)-alkyl to a straight-chain or branched alkyl radical having 1 to 6 carbon atoms, in the case of (C1-C6)-alkyl to a straight-chain or branched alkyl radical having 1 to 4 carbon atoms, and in the case of (C1-C3)-alkyl to methyl. Preferred examples which may be mentioned are: methyl, ethyl, n-propyl, isopropyl, tert-butyl, n-pentyl and n-hexyl. A straight-chain or branched alkyl radical having 1 to 3 carbon atoms is particularly preferred.

[0041] (C1-C6)-Alkylthio represents for the purposes of the invention a straight-chain or branched alkylthio radical having 1 to 6, preferably 1 to 4, carbon atoms. Preferred examples which may be mentioned are: methylthio, ethylthio, n-propylthio, isopropylthio, tert-butylthio, n-pentylthio and n-hexylthio. A straight-chain or branched alkylthio radical having 1 to 3 carbon atoms is particularly preferred.

[0042] Mono-(C1-C6)-alkylamino represents for the purposes of the invention an amino group having a straight-chain or branched alkyl substituent which has 1 to 6, preferably 1 to 4, carbon atoms. Preferred examples which may be mentioned are: methylamino, ethylamino, n-propylamino, isopropylamino, cyclopropylamino, t-butylamino, n-pentylamino, cyclopentylamino and n-hexylamino.

[0043] Di-(C1-C6)-alkylamino represents for the purposes of the invention an amino group having two identically or different straight-chain or branched alkyl substituents each of which has 1 to 6, preferably 1 to 4, carbon atoms. Preferred examples which may be mentioned are: N,N-dimethylamino, N,N-diethylamino, N-ethyl-N-methylamino, N-methyl-N-n-propylamino, N-methyl-N-cyclopropylamino, N-isopropyl-N-n-propylamino, N-t-butyl-N-methylamino, N-ethyl-N-n-pentylamino and N-n-hexyl-N-methylamino.

[0044] Mono-(C1-C6)-alkylaminocarbonyl represents for the purposes of the invention an amino group having a straight-chain or branched alkyl substituent which has 1 to 6, preferably 1 to 4, carbon atoms and is bonded via a carbonyl group. Preferred examples which may be mentioned are: methylaminocarbonyl, ethylaminocarbonyl, n-propylaminocarbonyl, isopropylaminocarbonyl, cyclopropylaminocarbonyl, t-butylaminocarbonyl, n-pentylaminocarbonyl, cyclopentylaminocarbonyl and n-hexylaminocarbonyl.

[0045] Di-(C1-C6)-alkylaminocarbonyl represents for the purposes of the invention an amino group having two identical or different straight-chain or branched alkyl substituents each of which has 1 to 6, preferably 1 to 4, carbon atoms and which is bonded via a carbonyl group. Preferred examples which may be mentioned are: N,N-dimethylaminocarbonyl, N,N-diethylaminocarbonyl, N-ethyl-N-methylaminocarbonyl, N-methyl-N-n-propylaminocarbonyl, N-methyl-N-cyclopropylaminocarbonyl, N-isopropyl-N-n-propylaminocarbonyl, N-t-butyl-N-methylaminocarbonyl, N-ethyl-N-n-pentylaminocarbonyl and N-n-hexyl-N-methylaminocarbonyl.

[0046] (C1-C8)-Cycloalkyl represents for the purposes of the invention a cycloalkyl group having 3 to 8, preferably 5 to 7, carbon atoms. Preferred examples which may be mentioned are: cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl.

[0047] (C6-C10)-Aryl represents for the purposes of the invention an aromatic radical having 6 to 10 carbon atoms. Preferred aryl radicals are phenyl and naphthyl.

[0048] Halogen represents for the purposes of the invention generally fluorine, chlorine, bromine and iodine. Fluorine, chlorine and bromine are preferred. Fluorine and chlorine are particularly preferred.

[0049] 3- to 12-membered carbocyclyl represents for the purposes of the invention generally a mono- or polycyclic, carbocyclic radical having 3 to 12 ring atoms. 3- to 10-membered, in particular 3- to 8-membered, carbocyclyl are preferred. Mono- or bicyclic carbocyclyl is preferred. Monocyclic carbocyclyl is particularly preferred. The carbocyclyl radicals may be saturated or partially unsaturated. Saturated carbocyclyl radicals are preferred. Likewise preferred are (C3-C10)-cycloalkyl, very particularly (C4-C7)-cycloalkyl. Preferred examples which may be mentioned are: cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cycloheptyl, norborn-1-yl, norborn-2-yl, norborn-7-yl, norborn-2-en-7-yl, cyclooctyl, cubyl, cyclononyl, cyclodecyl, decalinyl, adamant-1-yl, adamant-2-yl.

[0050] 5- to 10-membered heteroaryl represents for the purposes of the invention generally an aromatic, mono- or bicyclic radical having 5 to 10 ring atoms and up to 5 heteroatoms from the series S, O and/or N. 5- to 6-membered heteroaryl having up to 4 heteroatoms are preferred. The heteroaryl radical may be bonded via a carbon atom or heteroatom. Preferred examples which may be mentioned are: thienyl, furyl, pyrrolyl, thiazolyl, oxazolyl, imidazolyl, pyridyl, pyrimidyl, pyridazinyl, indolyl, indazolyl, benzofuranyl, benzothiophenyl, quinolinyl, isoquinolinyl.

[0051] 4- to 12-membered and 5- to 7-membered heterocyclyl represent for the purposes of the invention generally a mono- or polycyclic, heterocyclic radical having, respectively, 4 to 12 and 5 to 7 ring atoms and up to 3, preferably 2, heteroatoms or hetero groups from the series N, O, S, SO, SO2. 5- to 7-membered heterocyclyl is preferred. Mono- or bicyclic heterocyclyl is preferred. Monocyclic heterocyclyl is particularly preferred. O, N and S are preferred as heteroatoms. The heterocyclyl radicals may be saturated or partially unsaturated. Saturated heterocyclyl radicals are preferred. The heterocyclyl radicals may be bonded via a carbon atom or a heteroatom. 5- to 7-membered, monocyclic saturated heterocyclyl radicals having up to two heteroatoms from the series O, N and S are particularly preferred. Preferred examples which may be mentioned are: tetrahydrofuran-2-yl, pyrrolidin-2-yl, pyrrolidin-3-yl, pyrrolinyl, piperidinyl, morpholinyl, perhydroazepinyl.

[0052] If radicals in the compounds of the invention are optionally substituted, the radicals may, unless otherwise specified, be substituted one or more times identically or differently. Substitution by up to three identical or different substituents is preferred.

[0053] Preference is given to compounds of the general formulae (I) and (Ia)

[0054] in which

[0055] A, E, Y, R1, R2, R3, R4, R5, R6, R7 R8 and R9 have the abovementioned meaning,

[0056] and where R6 and R7 are not both hydrogen,

[0057] and the salts, hydrates and/or solvates thereof,

[0058] with the exception of 2-[3-oxo-1-(phenylsulfonyl)-1,2,3,4-tetrahydro-2-quinoxalinyl]-N-phenylacetamide.

[0059] Particular preference is given to compounds of the general formulae (I) and (Ia)

[0060] in which

[0061] A is methylene, and

[0062] E, Y, R1, R2, R3, R4, R5, R6, R7, R8 and R9 have the abovementioned meaning,

[0063] and the salts, hydrates and/or solvates thereof,

[0064] with the exception of 2-[3-oxo-1-(phenylsulfonyl)-1,2,3,4-tetrahydro-2-quinoxalinyl]-N-phenylacetamide.

[0065] Particular preference is likewise given to compounds of the general formulae (I) and (Ia),

[0066] in which

[0067] Y is CO and

[0068] E, A, R1, R2, R3, R4, R5, R6, R7, R8 and R9 have the abovementioned meaning,

[0069] and the salts, hydrates and/or solvates thereof,

[0070] with the exception of 2-[3-oxo-1-(phenylsulfonyl)-1,2,3,4-tetrahydro-2-quinoxalinyl]-N-phenylacetamide.

[0071] Particular preference is likewise given to compounds of the general formulae (I) and (Ia)

[0072] in which

[0073] R5 is phenyl which is optionally substituted identically or differently by one to three radicals selected from the group of methyl, chlorine, trifluoromethyl, trifluoromethoxy,

[0074] E is a bond, and

[0075] A, Y, R1, R2, R3, R4, R6, R7, R8 and R9 have the abovementioned meaning,

[0076] and the salts, hydrates and/or solvates thereof,

[0077] with the exception of 2-[3-oxo-1-(phenylsulfonyl)-1,2,3,4-tetrahydro-2-quinoxalinyl]-N-phenylacetamide.

[0078] Particular preference is likewise given to compounds of the general formulae (I) and (Ia)

[0079] in which

[0080] A is (C1-C6)-alkanediyl,

[0081] E is a bond or (C1-C6)-alkanediyl,

[0082] Y is CO,

[0083] R1, R2, R3 and R4 are identical or different and are hydrogen, halogen, trifluoromethyl, trifluoromethoxy, hydroxyl, nitro, cyano, amino, (C1-C6)-alkyl, (C1-C6)-alkoxy, (C1-C6)-alkylthio, mono- or di-(C1-C6)-alkylamino, (C1-C6)-acyl, (C1-C6)-acyloxy, (C1-C6)-acylamino, (C1-C6)-alkoxycarbonyl, mono- or di-(C1-C6)-alkylaminocarbonyl, carbamoyl or carboxyl,

[0084] R5 is (C6-C10)-aryl or 5- to 10-membered heteroaryl, where aryl and heteroaryl are optionally substituted identically or differently by radicals selected from the group of halogen, trifluoromethyl, trifluoromethoxy, hydroxyl, nitro, cyano, amino, (C1-C6)-alkyl, (C1-C6)-alkoxy, phenoxy, (C1-C6)-alkylthio, mono- or di-(C1-C6)-alkylamino, (C1-C6)-acyl, (C1-C6)-acyloxy, (C1-C6)-acylamino, (C1-C6)-alkoxycarbonyl, mono- or di-(C1-C6)-alkylaminocarbonyl, carbamoyl, carboxyl, phenyl, 5- to 6-membered heteroaryl, propane-1,3-diyl, butane-1,4-diyl, 1,3-dioxapropane-1,3-diyl or 1,4dioxabutane-1,4-diyl,

[0085] in which phenoxy, phenyl and 5- to 6-membered heteroaryl are in turn optionally substituted identically or differently by trifluoromethyl, (C1-C6)-alkyl, (C1-C6)-alkoxy or halogen,

[0086] R6 and R7 are identical or different and are hydrogen, (C6-C10)-aryl, 5- to 10-membered heteroaryl, 3- to 12-membered carbocyclyl, 4- to 12-membered heterocyclyl, or

[0087] are (C1-C10)-alkyl which is optionally substituted by halogen or a radical selected from the group of (C1-C6)-alkoxy, (C6-C10)-aryl, 5- to 10-membered heteroaryl, 3- to 12-membered carbocyclyl and 4- to 12-membered heterocyclyl,

[0088] where aryl, heteroaryl, heterocyclyl and carbocyclyl are optionally substituted identically or differently by radicals selected from the group of halogen, trifluoromethyl, trifluoromethoxy, hydroxyl, nitro, cyano, amino, (C1-C6)-alkyl, (C3-C8)-cycloalkyl, 5- to 7-membered heterocyclyl, (C1-C6)-alkoxy, phenoxy, (C1-C6)-alkylthio, mono- or di-(C1-C6)-alkylamino, (C1-C6)-acyl, (C1-C6)-acyloxy, (C1-C6)-acylamino, (C1-C6)-alkoxycarbonyl, mono- or di-(C1-C6)-alkylaminocarbonyl, carbamoyl, carboxyl, phenyl, 5- to 6-membered heteroaryl, propane-1,3-diyl, butane-1,4-diyl, 1,3-dioxapropane-1,3-diyl or 1,4-dioxabutane-1,4-diyl,

[0089] or

[0090] R6 and R7 together with the nitrogen atom form a 4- to 12-membered heterocyclyl radical which is bonded via nitrogen and which is optionally substituted identically or differently by radicals selected from the group of halogen, trifluoromethyl, trifluoromethoxy, hydroxyl, nitro, cyano, amino, (C1-C6)-alkyl, (C1-C6)-alkoxy, mono- or di-(C1-C6)-alkylamino, (C1-C6)-acyloxy, (C1-C6)-acyl, (C1-C6)-acylamino, (C1-C6)-alkoxycarbonyl, mono- or di-(C1-C6)-alkylaminocarbonyl, carbamoyl, carboxyl, (C3-C8)-cycloalkyl and phenyl,

[0091] where alkyl, cycloalkyl and phenyl in turn are optionally substituted identically or differently by one to three radicals selected from the group of halogen, phenyl, (C1-C6)-alkyl, (C1-C6)-alkoxy and (C1-C6)-alkylthio, in which phenyl in turn is optionally substituted identically or differently by radicals selected from the group of halogen or methyl,

[0092] R8 is hydrogen,

[0093] R9 is hydrogen,

[0094] and the salts, hydrates and/or solvates thereof,

[0095] with the exception of 2-[3-oxo-1-(phenylsulfonyl)-1,2,3,4-tetrahydro-2-quinoxalinyl]-N-phenylacetamide.

[0096] Very particular preference is given to compounds of the general formulae (I) and (Ia)

[0097] in which

[0098] A is methylene or ethylene,

[0099] E is a bond, methylene or ethylene,

[0100] Y is CO,

[0101] R1, R2, R3 and R4 are identical or different and are hydrogen, halogen, methyl, ethyl, methoxy, ethoxy, carbamoyl or carboxyl,

[0102] R5 is (C6-C10)-aryl or 5- to 10-membered heteroaryl, where aryl and heteroaryl are optionally substituted identically or differently by radicals selected from the group of halogen, trifluoromethyl, trifluoromethoxy, methyl, ethyl, isopropyl, methoxy, ethoxy, phenoxy, dimethylamino, (C1-C6)-alkoxycarbonyl, carbamoyl, carboxyl, phenyl, 5- to 6-membered heteroaryl and butane-1,4-diyl,

[0103] where phenoxy, phenyl and 5- to 6-membered heteroaryl are optionally substituted by trifluoromethyl, (C1-C6)-alkyl, (C1-C6)-alkoxy or halogen,

[0104] R6 and R7 are identical or different and and are hydrogen, phenyl, 3- to 12-membered carbocyclyl, 4- to 12-membered heterocyclyl, where R6 and R7 are not both hydrogen, or

[0105] are (C1-C10)-alkyl which is optionally substituted by a radical selected from the group of halogen, (C1-C6)-alkoxy, (C6-C10)-aryl, 5- to 10-membered heteroaryl, 3- to 12-membered carbocyclyl and 4- to 12-membered heterocyclyl,

[0106] where aryl, heteroaryl, heterocyclyl and carbocyclyl are optionally substituted identically or differently by radicals selected from the group of halogen, trifluoromethyl, trifluoromethoxy, (C1-C6)-alkyl, (C3-C8)-cycloalkyl, 5- to 7-membered heterocyclyl, (C1-C6)-alkoxy, phenoxy, (C1-C6)-alkoxycarbonyl, carbamoyl, carboxyl, phenyl, 5- to 6-membered heteroaryl and butane-1,4-diyl,

[0107] or

[0108] R6 and R7 together with the nitrogen atom form a 4- to 12-membered heterocyclyl radical which is bonded via nitrogen and which is optionally substituted identically or differently by one to three radicals selected from the group of halogen, trifluoromethyl, trifluoromethoxy, (C1-C6)-alkyl, (C1-C6)-alkoxy, (C1-C6)-alkoxycarbonyl, carbamoyl, carboxyl, (C3-C8)-cycloalkyl and phenyl,

[0109] where alkyl, cycloalkyl and phenyl in turn are optionally substituted identically or differently by radicals selected from the group of halogen, phenyl, (C1-C6)-alkyl und (C1-C6)-alkoxy,

[0110] R8 is hydrogen or (C1-C3)-alkyl which is optionally substituted by fluorine,

[0111] R9 is hydrogen or (C1-C6)-alkyl,

[0112] and the salts, hydrates and/or solvates thereof,

[0113] with the exception of 2-[3-oxo-1-(phenylsulfonyl)-1,2,3,4-tetrahydro-2-quinoxalinyl]-N-phenylacetamide.

[0114] Very particular preference is likewise given to compounds of the general formulae (I) and (Ia)

[0115] in which

[0116] A is methylene or ethylene,

[0117] E is a bond, methylene or ethylene,

[0118] Y is CO,

[0119] R1, R2, R3 and R4 are identical or different and are hydrogen, halogen, methyl, ethyl, methoxy, ethoxy, carbamoyl or carboxyl,

[0120] R5 is (C6-C10)-aryl or 5- to 10-membered heteroaryl, where aryl and heteroaryl are optionally substituted identically or differently by radicals selected from the group of halogen, trifluoromethyl, trifluoromethoxy, methyl, ethyl, isopropyl, methoxy, ethoxy, phenoxy, dimethylamino, (C1-C6)-alkoxycarbonyl, carbamoyl, carboxyl, phenyl, 5- to 6-membered heteroaryl and butane-1,4-diyl,

[0121] where phenoxy, phenyl and 5- to 6-membered heteroaryl are optionally substituted by trifluoromethyl, (C1-C6)-alkyl, (C1-C6)-alkoxy or halogen,

[0122] R6 and R7 are identical or different and are hydrogen, phenyl, 3- to 12-membered carbocyclyl, 4- to 12-membered heterocyclyl, where R6 and R7 are not both hydrogen, or

[0123] are (C1-C10)-alkyl which is optionally substituted by a radical selected from the group of halogen, (C1-C6)-alkoxy, (C6-C10)-aryl, 5- to 10-membered heteroaryl, 3- to 12-membered carbocyclyl and 4- to 12-membered heterocyclyl,

[0124] where aryl, heteroaryl, heterocyclyl and carbocyclyl are optionally substituted identically or differently by radicals selected from the group of halogen, trifluoromethyl, trifluoromethoxy, (C1-C6)-alkyl, (C3-C8)-cycloalkyl, 5- to 7-membered heterocyclyl, (C1-C6)-alkoxy, phenoxy, (C1-C6)-alkoxycarbonyl, carbamoyl, carboxyl, phenyl, 5- to 6-membered heteroaryl and butane-1,4-diyl,

[0125] or

[0126] R6 and R7 together with the nitrogen atom form a 4- to 12-membered heterocyclyl radical which is bonded via nitrogen and which is optionally substituted identically or differently by one to three radicals selected from the group halogen, trifluoromethyl, trifluoromethoxy, (C1-C6)-alkyl, (C1-C6)-alkoxy, (C1-C6)-alkoxycarbonyl, carbamoyl, carboxyl, (C3-C8)-cycloalkyl and phenyl,

[0127] where alkyl, cycloalkyl and phenyl in turn are optionaly substituted identically or differently by radicals selected from the group of halogen, phenyl, (C1-C6)-alkyl and (C1-C6)-alkoxy,

[0128] R8 is hydrogen,

[0129] R9 is hydrogen,

[0130] and the salts, hydrates and/or solvates thereof,

[0131] with the exception of 2-[3-oxo-1-(phenylsulfonyl)-1,2,3,4-tetrahydro-2-quinoxalinyl]-N-phenylacetamide.

[0132] Very particular preference is likewise given to compounds of the general formulae (I) and (Ia)

[0133] in which

[0134] A is methylene,

[0135] E is a bond,

[0136] Y is CO,

[0137] R1, R2 R3 and R4 are identical or different and each is hydrogen, methyl or halogen,

[0138] R5 is phenyl which is optionally substituted identically or differently by one to three radicals selected from the group of methyl, isopropyl, methoxy, ethoxy, halogen, p-chlorophenoxy, trifluoromethyl and trifluoromethoxy,

[0139] R6 and R7 are identical or different and

[0140] are hydrogen, phenyl or 5- to 8-membered carbocyclyl, where R6 and R7 are not both hydrogen,

[0141] or

[0142] are (C1-C6)-alkyl which is optionally substituted by a radical selected from the group of (C1-C6)-alkoxy, phenyl, 5- to 8-membered carbocyclyl and 5- to 8-membered heterocyclyl,

[0143] where phenyl, heterocyclyl and carbocyclyl are optionally substitituted identically or differently by one to three radicals selected from the group of halogen, trifluoromethyl, trifluoromethoxy, (C1-C6)-alkyl, (C3-C8)-cycloalkyl, 5- to 7-membered heterocyclyl, (C1-C6)-alkoxy, (C1-C6)-alkoxycarbonyl and butane-1,4-diyl, and

[0144] R8 is hydrogen,

[0145] R9 is hydrogen,

[0146] and the salts, hydrates and/or solvates thereof,

[0147] with the exception of 2-[3-oxo-1-(phenylsulfonyl)-1,2,3,4-tetrahydro-2-quinoxalinyl]-N-phenylacetamide.

[0148] Very particular preference is likewise given to compounds of the general formulae (I) and (Ia)

[0149] in which

[0150] A is methylene,

[0151] E is a bond,

[0152] Y is CO,

[0153] R1, R2, R3 and R4 are identical or different and are hydrogen or halogen,

[0154] R5 is phenyl which is optionally substituted identically or differently by one to three radicals selected from the group of methyl, isopropyl, halogen, trifluoromethyl and trifluoromethoxy,

[0155] R6 and R7 are identical or different and

[0156] are hydrogen, (C1-C6)-alkyl, phenyl or 5- to 8-membered carbocyclyl, where R6 and R7 are not both hydrogen, and where carbocyclyl and phenyl is optionally substituted identically or differently by radicals selected from the group of halogen, trifluoromethyl, trifluoromethoxy, methyl and methoxy,

[0157] R8 is hydrogen,

[0158] R9 is hydrogen,

[0159] and the salts, hydrates and/or solvates thereof,

[0160] with the exception of 2-[3-oxo-1-(phenylsulfonyl)-1,2,3,4-tetrahydro-2-quinoxalinyl]-N-phenylacetamide.

[0161] The invention further relates to processes for preparing the compounds of the formulae (I) and (Ia).

[0162] In process

[0163] [A] compounds of the general formula (II) or (IIa) 2

[0164] in which

[0165] A, E, Y, R1, R2, R3, R4, R5, R8 and R9 have the abovementioned meaning, and

[0166] X1 is halogen, preferably bromine or chlorine, or hydroxyl,

[0167] are reacted with compounds of the general formula (III) 3

[0168] or the salts thereof, e.g. hydrochloride or hydrobromide salts,

[0169] in which

[0170] R6 and R7 have the abovementioned meaning

[0171] in the case where X1 is halogen,

[0172] in inert solvents, where appropriate in the presence of a base, preferably in a temperature range from 0° C. to 50° C. under atmospheric pressure, to give compounds of the general formula (I) or (Ia).

[0173] Examples of inert solvents are halohydrocarbons such as methylene chloride, trichloromethane, tetrachloromethane, trichloroethane, tetrachloroethane, 1,2-dichloroethane or trichloroethylene, ethers such as diethyl ether, methyl tert-butyl ether, dioxane, tetrahydrofuran, glycol dimethyl ether or diethylene glycol dimethyl ether, hydrocarbons such as benzene, xylene, toluene, hexane, cyclohexane or petroleum fractions, or other solvents such as nitromethane, ethyl acetate, acetone, dimethylformamide, dimethylacetamide, 1,2-dimethoxyethane, 2-butanone, dimethyl sulfoxide, acetonitrile, pyridine or hexamethylphosphoric triamide, with preference for tetrahydrofuran or methylene chloride.

[0174] Examples of bases are alkali metal hydroxides such as sodium or potassium hydroxide, or alkali metal carbonates such as cesium carbonate, sodium or potassium carbonate, or amides such as lithium diisopropylamide, or other bases such as DBU, triethylamine or diisopropylethylaamine, preferably triethylamine.

[0175] In the case where X1 is hydroxyl,

[0176] compounds of the general formula (II) or (IIa)

[0177] are reacted in inert solvents in the presence of conventional condensing agents, where appropriate in the presence of a base, preferably in a temperature range from room temperature to 50° C. under atmospheric pressure, to give compounds of the general formula (I) or (Ia).

[0178] Examples of inert solvents are halohydrocarbons such as methylene chloride, trichloromethane, tetrachloromethane, trichloroethane, tetrachloroethane, 1,2 dichloroethane or trichloroethylene, ethers such as diethyl ether, methyl tert-butyl ether, dioxane, tetrahydrofuran, glycol dimethyl ether or diethylene glycol dimethyl ether, hydrocarbons such as benzene, xylene, toluene, hexane, cyclohexane or petroleum fractions, or other solvents such as nitromethane, ethyl acetate, acetone, dimethylformamide, dimethylacetamide, 1,2 dimethoxyethane, dimethyl sulfoxide, acetonitrile or pyridine, with preference for tetrahydrofuran, dimethylformamide or methylene chloride.

[0179] Examples of conventional condensing agents are carbodiimides such as, for example, N,N′-diethyl-, N,N,′-dipropyl-, N,N′-diisopropyl-, N,N′-dicyclohexylcarbodiimide, N-(3-dimethylaminoisopropyl)-N′-ethylcarbodiimide hydrochloride (EDC), N-cyclohexylcarbodiimide-N′-propyloxymethyl-polystyrene (PS-carbodiimide) or carbonyl compounds such as carbonyldiimidazole, or 1,2-oxazolium compounds such as 2-ethyl-5-phenyl-1,2-oxazolium-3-sulfate or 2-tert-butyl-5-methylisoxazolium perchlorate, or acylamino compounds such as 2-ethoxy-1-ethoxycarbonyl-1,2-dihydroquinoline, or propanephosphonic acid, or isobutyl chloroformate, or bis(2-oxo-3-oxazolidinyl)phosphoryl chloride or benzotriazolyloxytri(dimethylamino)phosphonium hexafluorophosphate, or O-(benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate (HBTU), 2-(2-oxo-1-(2H)-pyridyl)-1,1,3,3-tetramethyluronium tetrafluoroborate (TPTU) or O-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate (HATU), or 1-hydroxybenzotriazole (HOBt), or benzotriazol-1-yloxytris(dimethylamino)-phosphonium hexafluorophosphate (BOP), or mixtures thereof.

[0180] Examples of bases are alkali metal carbonates such as, for example, sodium or potassium carbonate, or bicarbonate, or organic bases such as trialkylamines, e.g. triethylamine, N-methylmorpholine, N-methylpiperidine, 4-dimethylaminopyridine or diisopropylethylamine.

[0181] Particular preference is given to the combination of N-(3-dimethylaminoisopropyl)-N′-ethylcarbodiimide hydrochloride (EDC) and 1-hydroxybenzotriazole (HOBt), and to the combination of N-cyclohexylcarbodiimide-N′-propyloxymethyl-polystyrene (PS-carbodiimide) and 1-hydroxybenzotriazole (HOBt) and to the combination of O-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate (HATU) and diisopropylethylamine.

[0182] The compounds of the general formula (III) are known or can be synthesized from the appropriate precursors by known processes.

[0183] The preparation of the compounds of the general formulae (II) and (IIa) is described hereinafter: (II-1) and (IIa-1) for Y═CO, (II-2) and (IIa-2) for Y═SO2.

[0184] In process

[0185] [B] compounds of the general formula (Ib) 4

[0186] in which

[0187] A, E, Y, R1, R2, R3, R4, R5, R6, R7 and R8 have the abovementioned meaning, are reacted

[0188] with compounds of the general formula (IV),

X2—R10  (IV)

[0189] in which

[0190] R10 is (C1-C6)-alkyl, and

[0191] X2 is halogen, preferably bromine or iodine,

[0192] in inert solvents in the presence of a base, where appropriate in the presence of potassium iodide, preferably in a temperature range from room temperature to the reflux of the solvent under atmospheric pressure, to give compounds of the general formula (I) or (Ia).

[0193] Examples of inert solvents are halohydrocarbons such as methylene chloride, trichloromethane or 1,2-dichloroethane, ethers such as dioxane, tetrahydrofuran or 1,2-dimethoxyethane, or other solvents such as acetone, dimethylformamide, dimethylacetamide, 2-butanone or acetonitrile, preferably tetrahydrofuran and methylene chloride.

[0194] Examples of bases are alkali metal carbonates such as cesium carbonate, sodium or potassium carbonate, or sodium or potassium methanolate, or sodium or potassium ethanolate or potassium tert-butoxide, or other bases such as sodium hydride, potassium hexadimethyldisilazide, lithium hexadimethyldisilazide or DBU, preferably potassium hexadimethyldisilazide or sodium hydride.

[0195] The compounds of the general formula (IV) are known or can be synthesized from the appropriate precursors by known processes.

[0196] In process

[0197] [C] compounds of the general formula (V) 5

[0198] in which

[0199] A, Y, R1, R2, R3, R4, R6, R7 and R8 have the abovementioned meaning, are reacted

[0200] with compounds of the general formula (VI), 6

[0201] in which

[0202] E and R5 have the abovementioned meaning, and

[0203] X3 is halogen, preferably bromine or chlorine,

[0204] in inert solvents, where appropriate in the presence of a base, preferably in a temperature range from room temperature to the reflux of the solvent under atmospheric pressure, to give compounds of the general formula (Ib).

[0205] Examples of inert solvents are halohydrocarbons such as methylene chloride, trichloromethane or 1,2-dichloroethane, ethers such as diethyl ether, dioxane, tetrahydrofuran or 1,2-dimethoxyethane, hydrocarbons such as benzene, xylene or toluene, or other solvents such as acetone, dimethylformamide, 2-butanone, acetonitrile or pyridine, with preference for pyridine, acetonitrile, methylene chloride or tetrahydrofuran.

[0206] Examples of bases are alkali metal carbonates such as cesium carbonate, sodium or potassium carbonate, or sodium or potassium methanolate, or sodium or potassium triethylamine, diisopropylethylamine or pyridine, with preference for alkali metal carbonates such as cesium carbonate, sodium or potassium carbonate or pyridine.

[0207] The compounds of the general formula (VI) are known or can be synthesized from the appropriate precursors by known processes.

[0208] The compounds of the general formula (V) can be prepared from the appropriate precursors in analogy to synthetic processes indicated hereinafter for the compounds of the general formula (X).

[0209] Compounds of the general formula (Va) 7

[0210] in which

[0211] R1, R2, R3, R4, R6 and R8 have the abovementioned meaning,

[0212] are prepared by reacting compounds of the general formula (VII) 8

[0213] in which

[0214] R1, R2, R3 and R4 have the abovementioned meaning,

[0215] with compounds of the general formula (VIII) 9

[0216] in which

[0217] R6 and R8 have the abovementioned meaning,

[0218] in inert solvents, preferably in a temperature range from room temperature to the reflux of the solvent under atmospheric pressure.

[0219] Examples of inert solvents are alcohols such as methanol, ethanol, n-propanol, isopropanol, n-butanol or tert-butanol, or mixtures of said solvents, where appropriate with water, with preference for a mixture of ethanol and water.

[0220] The compounds of the general formulae (VII) and (VIII) are known or can be synthesized from the appropriate precursors by known processes (cf. for (VIII): J. Romanenko, et al., Chem. Heterocycl. Compd. (Engl. Trans.) 9, 1973, 244).

[0221] Compounds of the general formula (II-1) or (IIa-1) are prepared by reacting compounds of the general formula (IX) or (IXa) 10

[0222] in which

[0223] A, E, R1, R2, R3, R4, R5, R8 and R9 have the abovementioned meaning, and

[0224] R11 is (C1-C6)-alkyl, preferably methyl and ethyl,

[0225] with bases, in inert solvents, preferably in a temperature range from room temperature to 60° C. under atmospheric pressure.

[0226] Examples of bases are alkali metal hydroxides such as sodium, lithium or potassium hydroxide, or alkali metal carbonates such as cesium carbonate, sodium or potassium carbonate, preferably sodium hydroxide or lithium hydroxide.

[0227] Examples of inert solvents are halohydrocarbons such as methylene chloride, tetrachloromethane, trichloroethane, tetrachloroethane, 1,2-dichloroethane or trichloroethylene, ethers such as diethyl ether, methyl tert-butyl ether, 1,2-dimethoxyethane, dioxane, tetrahydrofuran, glycol dimethyl ether or diethylene glycol dimethyl ether, alcohols such as methanol, ethanol, n-propanol, isopropanol, n-butanol or tert-butanol, or mixtures of said solvents, where appropriate with water, preferably tetrahydrofuran and/or methanol or a mixture of water and ethanol or a mixture of water and dioxane.

[0228] Compounds of the general formula (IX) or (IXa) when R9═R10 are prepared by reacting compounds of the general formula (IXb) 11

[0229] in which

[0230] A, E, R1, R2, R3, R4, R5, R8 and R11 have the abovementioned meaning,

[0231] with compounds of the general formula (IV) under the reaction conditions described in process [B].

[0232] Compounds of the general formula (IXb) are prepared by reacting compounds of the general formula (X) 12

[0233] in which

[0234] A, R1, R2, R3, R4, R8 and R11 have the abovementioned meaning,

[0235] with compounds of the general formula (VI) under the reaction conditions described in process [C].

[0236] Compounds of the general formula (X) are prepared by reacting compounds of the general formula (XI) 13

[0237] in which

[0238] A, R1, R2, R3, R4, R8 and R11 have the abovementioned meaning, and

[0239] R12 is (C1-C6)-alkyl, preferably methyl and ethyl,

[0240] under with a reducing agent in inert solvents, preferably in a temperature range from room temperature to the reflux of the solvent under atmospheric pressure up to 3 bar (cf. R. C. Larock, Comprehensive Organic Transformations, VCH Verlagsgesellschaft, 1989, pages 411-415).

[0241] Examples of reducing agents are palladium on activated carbon and hydrogen, tin dichloride or titanium trichloride, with preference for palladium on activated carbon and hydrogen or tin dichloride.

[0242] Examples of inert solvents are ethers such as diethyl ether, methyl tert-butyl ether, 1,2-dimethoxyethane, dioxane, tetrahydrofuran, glycol dimethyl ether or diethylene glycol dimethyl ether, alcohols such as methanol, ethanol, n-propanol, isopropanol, n-butanol or tert-butanol, hydrocarbons such as benzene, xylene, toluene, hexane, cyclohexane or petroleum fractions, or other solvents such as ethyl acetate, dimethylformamide, dimethylacetamide, acetonitrile or pyridine, preferred solvents being methanol, ethanol, isopropanol or, in the case of tin dichloride, in ethanol, methanol or dimethylformamide.

[0243] Compounds of the general formula (XI) are prepared by reacting compounds of the general formula (XII) 14

[0244] in which

[0245] R1, R2, R3 and R4 have the abovementioned meaning,

[0246] with compounds of the general formula (XIII), 15

[0247] in which

[0248] A, R8, R11 and R12 have the abovementioned meaning,

[0249] or the salts thereof, e.g. hydrochloride or hydrobromide salts,

[0250] in inert solvents, where appropriate in the presence of a base, preferably in a temperature range from room temperature to the reflux of the solvent under atmospheric pressure.

[0251] Examples of inert solvents are ethers such as 1,2-dimethoxyethane, dioxane, glycol dimethyl ether or diethylene glycol dimethyl ether, hydrocarbons such as benzene, xylene, toluene or petroleum fractions, or other solvents such as dimethylformamide, dimethylacetamide, dimethyl sulfoxide, acetonitrile or pyridine, with dimethyl sulfoxide being preferred as solvent.

[0252] Examples of bases are alkali metal carbonates such as cesium carbonate, sodium or potassium carbonate, or amides such as sodamide, lithium bis(trimethylsilyl)amide, lithium diisopropylamide, or organometallic compounds such as butyllithium or phenyllithium, or other bases such as sodium hydride, DBU, triethylamine or diisopropylethylamine, preferably diisopropylethylamine or triethylamine.

[0253] The compounds of the general formulae (XII) and (XIII) are known or can be synthesized from the appropriate precursors by known processes [cf. for (VIII): Drysdale et al. Bioorg. Med. Chem. Lett. 1998, 8, 133-138.4; Aitken et al. Synthesis 1997, 787-791; Larsson et al. Acta Chem. Scand. 1994, 48, 517-525, Trost et al. J. Org. Chem. 1988, 53, 532).

[0254] Compounds of the general formula (II-2) or (IIa-2) 16

[0255] in which

[0256] A, E, R1, R2, R3, R4, R5, R8 and R9 have the abovementioned meaning, and

[0257] X4 is halogen, preferably chlorine,

[0258] are prepared by reacting compounds of the general formula (XIV) or (XIVa), 17

[0259] in which

[0260] A, E, R1, R2, R3, R4, R5, R8 and R9 have the abovementioned meaning,

[0261] with potassium nitrate and sulfuryl chloride in inert solvents, preferably in a temperature range from room temperature to the reflux of the solvent at atmospheric pressure.

[0262] Examples of inert solvents are halohydrocarbons such as methylene chloride, trichloromethane, tetrachloromethane, trichloroethane, tetrachloroethane, 1,2-dichloroethane or trichloroethylene, ethers such as 1,2-dimethoxyethane, dioxane, tetrahydrofuran, glycol dimethyl ether or diethylene glycol dimethyl ether, alcohols such as methanol, ethanol, n-propanol, isopropanol, n-butanol or tert-butanol, hydrocarbons such as benzene, xylene, toluene, hexane, cyclohexane or petroleum fractions, or other solvents such as ethyl acetate, dimethylformamide, dimethylacetamide, dimethyl sulfoxide, acetonitrile or pyridine, with acetonitrile being preferred as solvent. 1819

[0263] The compounds of the general formula (I) of the invention are suitable for use as medicaments for the treatment and/or prophylaxis of diseases in humans and animals.

[0264] The compounds of the invention show a valuable range of pharmacological effects which could not have been predicted.

[0265] The compounds of the invention have B1 receptor antagonistic effects.

[0266] The compounds of the invention can, by reason of their pharmacological properties, be employed alone or in combination with other medicaments for the prophylaxis and treatment of acute and/or chronic pain (for a classification, see “Classification of Chronic Pain, Descriptions of Chronic Pain Syndromes and Definitions of Pain Terms”, 2nd Edition., Meskey and Begduk, Editors; IASP-Press, Seattle, 1994), especially for the treatment of cancer-induced pain and chronic neuropathic pain such as, for example, associated with diabetic neuropathy, post-herpetic neuralgia, peripheral nerve damage, central pain (for example resulting from cerebral ischemia) and trigeminal neuralgia, and other chronic pain such as, for example, lumbago, (low) back pain, inflammatory or rheumatic pain. These substances are moreover suitable for the therapy of primarily acute pain of any etiology and of secondary states of pain resulting therefrom, and for the therapy of states of pain which were formerly acute and have become chronic.

[0267] Bradykinin 1 antagonists are furthermore suitable for the treatment of asthma, diabetic vasculopathy, rhinitis, septic shock, atherosclerosis, multiple sclerosis or rheumatoid arthritis.

[0268] The in vitro effect of the compounds of the invention can be shown using the following biological assays:

[0269] 1. Functional in vitro Assay

[0270] Agonists such as des-Arg9-BK and des-Arg10-kallidin activate the B1 receptor and lead, via stimulation of phospholipase C, to release of calcium ions from intracellular stores. Antagonists block the activation of the receptor by the agonists and thus also the agonist-dependent stimulation of phospholipase C and the intracellular calcium release induced thereby.

[0271] A functional in vitro assay can be carried out with stable cell lines, e.g. CHO or HEK 293, which recombinantly express the human B1 receptor. This entails measuring the activation of the receptor by the agonist indirectly via the intracellular calcium release induced thereby (in microtiter plates with 96, 384 and 1536 wells/plate). The effect of the tested substances can be stated as IC50.

[0272] In this assay, Examples 170 and 177 have IC50 values of 25 nM and 17 nM, respectively.

[0273] 2. Binding to CHO BK1 Membranes

[0274] The binding of ligands to the B1 receptor from B1-transfected CHO cell membranes is carried out by the method of Levesque et al. (Immunopharmacol. 1995, 29, 141-147). Incubation buffer (Tris-HCl buffer pH 7.4+1 mM phenanthrolines, 0.14 g/l bacitracin), labeled radioligand [3H]-desArg10-kallidin (0.5 nM), DMSO or test stubstance all pipetted together, and then 250 μg of protein are added, and the mixture is thoroughly mixed and incubated at RT for 90 min. After expiry of the incubation time, the reaction is stopped by adding ice-cold Tris-HCl buffer to each tube. Filtration through Whatman GF/B filters (in 0.6% polyetylenimines) is followed by washing with 2×3 ml of Tris-HCl buffer. The filters are transferred into minivials, and the radioactivity is determined in a liquid scintillation counter. The effect of the tested substances can be stated as Ki or IC50.

[0275] The suitability of the compounds of the invention for the treatment of states of pain, especially neuropathic states of pain, can be shown in the following animal models:

[0276] 3. Model of Acute Inflammatory Pain (Carrageenin Model) in Rats

[0277] This model follows the description by Winter et al. (Proc. Soc. Exp. Biol. Med., 1962, 111, 544-547).

[0278] Rats receive subplantar injections of a suspension of carrageenin in the right rear paw (0.35 mg per paw in 0.10 ml of physiological saline). Two hours later, the rats are thermally stimulated successively on the noninflamed and on the inflamed rear paw.

[0279] The thermal stimulation apparatus (Ugo Basile, Ref.: 7371) consists of 6 individual Plexiglas boxes (17×11×13 cm) placed on an elevated glass plate. A rat is is put in the box for 30 min for habituation. Then a movable infrared source (Setting 20) is focussed under the noninflamed and the inflamed rear paw, and the latency times until the paw is withdrawn are recorded automatically. The withdrawal of the paw interrupts the reflected beam and thus automatically switches off the counter and light source. To avoid tissue damage, the test is stopped after 45 s even if no paw-withdrawal response is recorded.

[0280] At least 12 rats are investigated in each group: male Wistar (Han) rats, 180-220 g. The test is carried out blind.

[0281] The data are analyzed by comparing the treated groups with the corresponding control by means of the unpaired Student's test.

[0282] The novel active ingredients can be converted in a known manner into conventional formulations such as tablets, coated tablets, pills, granules, aerosols, syrups, emulsions, suspensions and solutions, using inert, nontoxic, pharmaceutically suitable carriers or solvents. In these, the therapeutically active compound should be present in each case in a concentration of about 0.5 to 90% by weight of the complete mixture, i.e. in amounts which are sufficient to achieve the stated dosage range.

[0283] The formulations are produced for example by extending active ingredients with solvents and/or carriers, where appropriate with use of emulsifiers and/or dispersants, it being possible, for example when water is used as diluent, where appropriate to use organic solvents as auxiliary solvents.

[0284] Administration takes place in a conventional way, preferably orally, transdermally or parenterally, especially perlingually or intravenously. However, it can also take place by inhalation through the mouth or nose, for example with the aid of a spray, or topically via the skin.

[0285] It has generally proved advantageous to administer amounts of about 0.001 to 25 mg/kg, preferably about 0.1 to 10 mg/kg, of body weight, on oral use about 0.01 to 25 mg/kg, preferably about 0.5 to 5 mg/kg, of body weight to achieve effective results.

[0286] It may nevertheless be necessary where appropriate to deviate from the amounts mentioned, in particular as a function of the body weight and the mode of administration, of the individual response to the medicament, of the nature of its formulation and the time or interval over which administration takes place. Thus, in some cases it may sufficient to make do with less than the aforementioned minimum amount, whereas in other cases the upper limit mentioned must be exceeded. Where larger amounts are administered, it may be advisable to distribute these in a plurality of single doses over the day.

[0287] Abbreviations:

[0288] abs. absolute

[0289] Ac acetyl

[0290] acac acetylacetonyl

[0291] AIBN α, α′-azobis(isobutyronitrile)

[0292] Aloc allyloxycarbonyl

[0293] aq. aqueous

[0294] 9-BBN 9-borabicyclo[3.3.1]nonane

[0295] Bn benzyl

[0296] Boc tert-butoxycarbonyl

[0297] Bom benzyloxymethyl

[0298] BOP benzotriazol-1-yloxytris(dimethylamino)phosphonium hexafluorophosphate

[0299] b.p. boiling point

[0300] Bu butyl

[0301] Bz benzoyl

[0302] CAN cerium ammonium nitrate

[0303] Cbz benzyloxycarbonyl

[0304] CDI N,N′-carbonyldiimidazole

[0305] cf. compare

[0306] CH cyclohexane

[0307] conc. concentrated

[0308] Cp cyclopentadienyl

[0309] cryst. crystalline/crystallized

[0310] CSA 10-camphorsulfonic acid

[0311] Dabco 1,4-diazabicyclo[2.2.2]octane

[0312] DAST diethylaminosulfur trifluoride

[0313] DBN 1,5-diazabicyclo[4.3.0]non-5-ene

[0314] DBU 1,8-diazabicyclo[5.4.0]undec-7-ene

[0315] DCC N,N′-dicyclohexylcarbodiimide

[0316] DCE 1,2-dichloroethane

[0317] DCI direct chemical ionization (in MS)

[0318] DCM dichloromethane

[0319] DDQ 2,3-dichloro-5,6-dicyano-1,4-benzoquinone

[0320] DEAD diethyl azodicarboxylate

[0321] d.e. diastereomeric excess

[0322] decomp. decomposition

[0323] DHP 3,4-dihydro-2h-pyran

[0324] DIAD diisopropyl azodicarboxylate

[0325] DIBAH diisobutylaluminum hydride

[0326] DIC diisopropylcarbodiimide

[0327] DIEA N,N-diisopropylethylamine

[0328] dil. dilute

[0329] dist. distilled

[0330] DMA N,N-dimethylacetamide

[0331] DMAP 4-N,N-dimethylaminopyridine

[0332] DME 1,2-dimethoxyethane

[0333] DMF N,N-dimethylformamide

[0334] DMPU N,N′-dimethylpropyleneurea

[0335] DMSO dimethyl sulfoxide

[0336] DNPH 2,4-dinitrophenylhydrazine

[0337] DPPA diphenylphosphoryl azide

[0338] EDC N′-(3-dimethylaminopropyl)-n-ethylcarbodiimide×HCl

[0339] e.e. enantiomeric excess

[0340] EA ethyl acetate (acetic acid ethyl ester)

[0341] EI electron impact ionization (in MS)

[0342] eq equivalent(s)

[0343] ESI electrospray ionization (in MS)

[0344] Et ethyl

[0345] Fmoc fluorenylmethoxycarbonyl

[0346] Fr. fraction

[0347] GC gas chromatography

[0348] HATU O-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate

[0349] HBTU O-(benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate

[0350] HMDS 1,1,1,3,3,3-hexamethyldisilazane

[0351] HMPA or HMPT hexamethylphosphoric triamide

[0352] HOBt 1-hydroxy-1H-benzotriazole×H2O

[0353] HOSu N-hydroxysuccinimide

[0354] HPLC high pressure, high performance liquid chromatography

[0355] Im imidazol-1-yl

[0356] IR infrared spectroscopy

[0357] LAH lithium aluminum hydride

[0358] LC-MS coupled liquid chromatography-mass spectroscopy

[0359] LDA lithium N,N-diisopropylamide

[0360] LiHMDS lithium N,N-bistrimethylsilylamide

[0361] Lit. literature (reference)

[0362] Liq. liquid

[0363] m meta

[0364] mCPBA meta-chloroperbenzoic acid

[0365] Me methyl

[0366] MEK methyl ethyl ketone

[0367] MEM methoxyethoxymethyl

[0368] MOM methoxymethyl

[0369] m.p. melting point

[0370] MPLC medium pressure liquid chromatography

[0371] Ms methanesulfonyl (mesyl)

[0372] MS mass spectroscopy

[0373] MTBE methyl tert-butyl ether

[0374] MW molecular weight

[0375] NBS N-bromosuccinimide

[0376] NCS N-chlorosuccinimide

[0377] NIS N-iodosuccinimide

[0378] NMM N-methylmorpholine

[0379] NMO N-methylmorpholine N-oxide

[0380] NMR nuclear magnetic resonance spectroscopy

[0381] o ortho

[0382] p para

[0383] p.A. analytical grade

[0384] PCC pyridinium chlorochromate

[0385] PDC pyridinium dichromate

[0386] Pfp pentafluorophenyl

[0387] Ph phenyl

[0388] Piv pivaloyl

[0389] PMB p-methoxybenzyl

[0390] PNB p-nitrobenzyl

[0391] PPA polyphosphoric acid

[0392] ppt. precipitate

[0393] PPTS pyridinium p-toluenesulfonate

[0394] Pr propyl

[0395] PS polystyrene (resin)

[0396] py pyridine

[0397] PyBOP benzotriazol-1-yloxytris(pyrrolidino)phosphonium hexafluorophosphate

[0398] RF reflux

[0399] Rf retention index (in TLC)

[0400] RP reverse phase (in HPLC)

[0401] RT room temperature

[0402] Rt retention time (in HPLC)

[0403] sat. saturated

[0404] SEM 2-(trimethylsilyl)ethoxymethyl

[0405] sol. solution

[0406] subl. sublimes

[0407] TBAF tetrabutylammonium fluoride

[0408] TBAI tetrabutylammonium iodide

[0409] TBDMS tert-butyldimethylsilyl

[0410] TBDPS tert-butyldiphenylsilyl

[0411] TBTU O-(benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium tetrafluoroborate

[0412] TEA triethylamine

[0413] techn. technical

[0414] Teoc 2-(trimethylsilyl)ethoxycarbonyl

[0415] TES triethylsilyl

[0416] Tf trifluoromethanesulfonyl

[0417] TFA trifluoroacetic acid

[0418] TFAA trifluoroacetic anhydride

[0419] TfOH trifluoromethanesulfonic acid

[0420] THF tetrahydrofuran

[0421] THP tetrahydropyranyl

[0422] TIPS triisopropylsilyl

[0423] titr. titrated

[0424] TLC thin layer chromatography

[0425] TMEDA N,N,N′,N′-tetramethylethylenediamine

[0426] TMOF trimethyl orthoformate

[0427] TMS trimethylsilyl

[0428] TPP triphenylphosphine

[0429] TPPO triphenylphosphine oxide

[0430] Trt trityl

[0431] Ts p-toluenesulfonyl (tosyl)

[0432] TsOH p-toluenesulfonic acid

[0433] v/v volume-to-volume ratio (of a solution)

[0434] Vol. volume

[0435] w/w weight-to-weight ratio (of a solution)

[0436] Z benzyloxycarbonyl

[0437] The LC-MS data were found by the following methods:

[0438] Method A

[0439] HPLC apparatus type: HP 1100

[0440] UV dectector DAD: 208-400 nm

[0441] Column: symmetry C 18; 50 mm×2.1 mm; 3.5 μm

[0442] Ionization: ESI positive/negative

[0443] Oven temperature: 40° C.

[0444] Solvent A: CH3CN+0.1% formic acid Solvent B: H2O+0.1% formic acid

[0445] Gradient:

	Time	A:%	B:%	Flow rate
	0.00	10.0	90.0	0.50
	4.00	90.0	10.0	0.50
	6.00	90.0	10.0	0.50
	6.10	10.0	90.0	1.00
	7.50	10.0	90.0	0.50

[0446] Method B

[0447] Column: symmetry C 18; 2.1 mm×150 mm; 5 μm

[0448] Ionization: ESI positive/negative

[0449] Oven temperature: 70° C.

[0450] Solvent B: 0.3 g of HCl (30%)/1 l of water

[0451] Gradient: A/B 2/98 to 95/5 within 2.5 min

[0452] Flow rate: 0.9 ml/min to 1.2 ml/min within 2 min

[0453] Method C

[0454] Instrument: HP 1100 with DAD detection;

[0455] Column: Kromasil RP-18, 60 mm×2 mm, 3.5 μm;

[0456] Eluent: A=5 ml HClO4/l H2O, B=ACN;

[0457] Gradient: 0 min 2% B, 0.5 min 2% B, 4.5 min 90% B, 6.5 min 90% B;

[0458] Flow rate: 0.75 ml/min; Temp.: 30° C.; Detection UV 210 nm

[0459] Starting Compounds

EXAMPLE I

N-Phenylmethyl-2-(3-oxo-1,2,3,4-tetrahydro-2-quinoxalinyl)acetamide

[0460] 20

[0461] A suspension of 5.00 g (46.2 mmol) of 1,2-phenylenediamine and 8.66 g (46.2 mmol) of N-(phenylmethyl)maleimide in 500 ml of 1:1 ethanol/water are heated to boiling. After refluxing for 4 hours, the mixture is allowed to cool and the resulting precipitate is removed. The filter cake is washed with 1:1 ethanol/water and dried in vacuo. 6.64 g (49%) of the target compound are obtained in this way as a yellowish solid. The filtrate is evaporated and the residue is triturated in isopropanol. A further 1.37 g (10%) are obtained in this way as a pale yellow solid.

[0462] 1 H-NMR (200 MHz, DMSO-d6): δ=2.43 (dd, 1H), 2.71 (m, 1H), 4.10-4.16 (m, 1H), 4.16-4.42 (m, 2H), 5.90 (s, br, 1H), 6.54-6.85 (m, 4H), 7.17-7.39 (m, 5H), 8.45 (t, 1H), 10.28 (s, br, 1H).

[0463] MS (ESI): m/z=296 [M+H]+.

EXAMPLE II

N-(2-Methoxyphenyl)-2-(3-oxo-1,2,3,4-tetrahydro-2-quinoxalinyl)acetamide

[0464] 21

[0465] This compound is obtained in analogy to the method of example I from 1.00 g (9.25 mmol) of 1,2-phenylenediamine and 1.88 g (9.25 mmol) of N-(2-methoxyphenyl)maleimide after refluxing for 3.5 hours and triturating the resulting precipitate with isopropanol.

[0466] Yield: 1.76 g (61%) as pale yellow solid.

[0467] 1 H-NMR (200 MHz, DMSO-d6): δ=2.52-2.98 (ABX system, AB part, 2H), 3.74 (s, 3H), 4.21 (dd, 1H), 6.04 (s, 1H), 6.55-7.10 (m, 7H), 8.06 (d, 1H), 9.43 (s, 1H), 10.33 (s, 1H).

[0468] MS (DCI, NH3): m/z=329 [M+NH4]+, 312 [M+H]+.

EXAMPLE III

Dimethyl N-(2-nitrophenyl)aspartate

[0469] 22

[0470] A solution of 53.6 g (380 mmol) of 1-fluoro-2-nitrobenzene, 25.0 g (127 mmol) of dimethyl DL-asparatate and 49.1 g (380 mmol) of N,N-diisopropylethylamine in 150 ml of DMSO is stirred in an argon atmosphere at 60° C. overnight. It is cooled to room temperature, and 300 ml each of water and ethyl acetate are added to the mixture. The aqueous phase is extracted three times with 300 ml of ethyl acetate each time, and the combined organic phases are washed twice with 100 ml of water each time. The organic phase is dried over sodium sulfate, and the solvent is distilled off in a rotary evaporator. The crude product is purified on a flash column (mobile phase: toluene). 21.8 g (61%) of the target compound are obtained.

[0471] HPLC: Kromasil C18 60×2 mm; Eluent: water+5‰ HClO4/acetonitrile, T=30° C., Flow rate=0.75 ml/min, Rt=4.3 min.

[0472] MS (DCI, NH3): m/z=300 [M+NH4]+, 283 [M+H]+, 582.4 [2M+NH4]+.

[0473] 1 H-NMR (200 MHz, CDCl3): δ=2.99 (d, 2H), 3.75 (s, 3H), 3.80 (s, 3H), 4.70 (m, 1H), 6.76 (dt, 1H), 6.85 (m, 1H), 7.48 (dt, 1H), 8.21 (dd, 1H), 8.52 (d, broad, 1H).

EXAMPLE IV

Methyl(3-oxo-1,2,3,4-tetrahydro-2-quinoxalinyl)acetate

[0474] 23

[0475] A solution of 22.0 g (77.9 mmol) of dimethyl N-(2-nitrophenyl)aspartate (example III) and catalytic amounts of palladium on activated carbon (10%) in 200 ml of methanol is stirred in a hydrogen atmosphere at room temperature for 48 h. Filtration with suction through kieselguhr is followed by washing with methanol. The solvent is distilled off in a rotary evaporator to result in 16.0 g (93%) of the desired product.

[0476] PLC: Kromasil C18 60×2 mm; Eluent: Water+5% HClO4/acetonitrile, T=30° C., Flow rate=0.75 ml/min, Rt=3.4 min.

[0477] MS (DCI, NH3): m/z=238.2 [M+NH4]+, 221.2 [M+H]+.

[0478] 1 H-NMR (200 MHz, CDCl3): δ=2.72 (dd, 1H), 3.14 (dd, 1H), 3.75 (s, 3H), 4.34 (dt, 1H), 4.73 (s, broad, 1H), 6.79-6.82 (m, 3H), 6.91 (m, 1H), 8.21 (s, broad, 1H).

EXAMPLE V

Methyl 2-[1-(mesitylsulfonyl)-3-oxo-1,2,3,4-tetrahydro-2-quinoxalinyl]acetate

[0479] 24

[0480] A solution of 4.00 g (18.2 mmol) of methyl 2-(3-oxo-1,2,3,4-tetrahydro-2-quinoxalinyl)acetate (example IV), 19.9 g (90.8 mmol) of 1,3,5-trimethylbenzenesulfonyl chloride and 12.5 g (90.8 mmol) of potassium carbonate in 100 ml of acetonitrile is stirred at 60° C. for 16 h. The solvent is distilled off in a rotary evaporator, and the residue is taken up in 50 ml of water and extracted three times with 100 ml of ethyl acetate each time. The combined organic phases are dried over sodium sulfate, and the solvent is distilled off in a rotary evaporator. The crude product is purified on a flash column (mobile phase: 9:1 toluene/ethyl acetate) to result in 4.55 g (62%) of the title compound.

[0481] HPLC: Kromasil C18 60×2 mm; Eluent: Water+5‰ HClO4/acetonitrile, T=30° C., Flow rate=0.75 ml/min, Rt=4.4 min.

[0482] MS (DCI, NH3): m/z=420.1 [M+NH4]+.

[0483] 1 H-NMR (200 MHz, CDCl3): δ=2.28 (s, 3H), 2.37 (m, 1H), 2.50 (s, 6H), 2.55 (m, 1H), 3.60 (s, 3H), 4.94 (dd, 1H), 6.82 (dd, 1H), 6.93 (s, 2H), 7.04 (m, 1H), 7.21 (m, 1H), 7.38 (m, 1H), 8.25 (s, broad, 1H).

EXAMPLE VI

2-[1-(Mesitylsulfonyl)-3-oxo-1,2,3,4-tetrahydro-2-quinoxalinyl]acetic acid

[0484] 25

[0485] 803 mg (33.5 mmol) of lithium hydroxide are added to a solution of 4.50 g (11.1 mmol) of methyl 2-[1-(mesitylsulfonyl)-3-oxo-1,2,3,4-tetrahydro-2-quinoxalinyl]acetate (example V) in 160 ml of water/ethanol (1:1) solution, and the mixture is stirred at RT for 4 h. Most of the ethanol is distilled off in a rotary evaporator, and the residue is mixed with 100 ml of ethyl acetate and adjusted to pH 2 with 1 molar aqueous hydrochloric acid. The aqueous phase is extracted six times with 100 ml of ethyl acetate each time. The combined organic phases are dried over sodium sulfate, and the solvent is distilled off in a rotary evaporator. 3.05 g (70%) of the title compound are obtained.

[0486] HPLC: Kromasil C18 60×2 mm; Eluent: Water+5‰ HClO4/acetonitrile, T=30° C., Flow rate=0.75 ml/min, Rt=4.0 min.

[0487] MS (ESI): m/z=389.2 [M+H]+.

[0488] 1 H-NMR (200 MHz, DMSO-d6): δ=2.11 (dd, 1H), 2.27 (s, 3H), 2.38 (s, 6H), 2.41 (m, 1H), 4.68 (dd, 1H), 6.94 (dd, 1H), 7.00 (m, 1H), 7.05 (s, 2H), 7.07 (m, 1H), (dt, 1H).

EXAMPLE VII

1-Cycloheptyl-1H-pyrrole-2,5-dione

[0489] 26

[0490] 10 g (102 mmol) of maleic anhydride are dissolved in 600 ml of toluene at room temperature and then 11.54 g (102 mmol) of cycloheptylamine dissolved in 100 ml of toluene are slowly added. The reaction solution is then stirred at room temperature for one hour. 22.97 g (102 mmol) of zinc bromide are then added to the reaction solution heated to 80° C., and 32.27 ml (153 mmol) of hexamethyldisilazane (in 100 ml of toluene) are added dropwise over the course of 30 min. The solution is subsequently heated to 100° C. and stirred overnight. After the reaction solution has cooled, the solution is added to 200 ml of 0.5N HCl, and the organic phase is separated. The aqueous phase is extracted three times more with 200 ml of ethyl acetate, the combined organic phases are dried over magnesium sulfate, and the solvent is distilled off in a rotary evaporator. The crude product is purified on a flash column (mobile phase: cyclohexane/ethyl acetate). 18.78 g (94%) of the title compound are obtained as a white solid.

[0491] 1 H-NMR (200 MHz, DMSO-d6): δ=1.28-1.81 (m, 10H), 1.88-2.01 (m, 2H), 3.84-4.03 (m, 1H), 6.96 (s, 2H).

[0492] LC-MS: Rt=9.20;

[0493] MS (EI): m/z=193 [M+].

EXAMPLE VIII

N-Cycloheptyl-2-(oxo-1,2,3,4-tetrahydro-2-quinoxalinyl)acetic acid

[0494] 27

[0495] A suspension of 6.72 g (62.1 mmol) of 1,2-phenylenediamine and 12 g (62.1 mmol) of 1-cycloheptyl-1H-pyrrole-2,5-dione in 200 ml of 1:1 ethanol/water are heated to boiling. After refluxing for 12 hours, the mixture is allowed to cool, and the resulting precipitate is removed. The filter cake is washed with 1:1 ethanol/water and dried in vacuo.

[0496] 16 g (85%) of the target compound are obtained in this way as a yellowish solid.

[0497] 1 H-NMR (300 MHz, DMSO-d6): δ=1.27-1.88 (m, 12H), 2.31 (dd, 1H), 2.59 (dd, 1H), 3.68-3.82 (m, 1H), 4.01-4.11 (m, 1H), 5.79 (s, br, 1H), 6.55-6.68 (m, 1H), 6.69-6.78 (m, 3H), 7.82 (d, 1H), 10.22 (s, br, 1H).

[0498] MS (ESI): m/z=302 [M+H]+.

[0499] Exemplary Embodiments

EXAMPLE 1

N-Cycloheptyl-2-[1-(mesitylsulfonyl)-3-oxo-1,2,3,4-tetrahydro-2-quinoxalinyl]-acetamnide

[0500] 28

[0501] A solution of 1.00 g (2.57 mmol) of 2-[1-(mesitylsulfonyl)-3-oxo-1,2,3,4-tetrahydro-2-quinoxalinyl]acetic acid (example VI), 291 mg (2.57 mmol) of cycloheptylamine, 383 mg (2.83 mmol) of 1-hydroxy-1H-benzotriazole, 567 mg (2.96 mmol) of EDC and 521 mg (5.15 mmol) of triethylamine in 10 ml of DMF is stirred at room temperature overnight. The mixture is taken up in 100 ml of ethyl acetate and washed three times with 30 ml of water each time. The organic phase is washed twice with saturated sodium chloride solution and dried over sodium sulfate, and the solvent is distilled off in a rotary evaporator. The crude product is purified on a flash column (mobile phase: 100:2 dichloromethane/methanol). 550 mg (44%) of the title compound are obtained.

[0502] HPLC: Kromasil C18 60×2 mm; Eluent: Water+5‰ HClO4/acetonitrile, T=30° C., Flow rate=0.75 ml/min, Rt=4.7 min.

[0503] MS (DCI, NH3): m/z=484.2 [M+H]+.

[0504] 1 H-NMR (300 MHz, CDCl3): δ=1.34-1.69 (m, 10H), 1.89 (m, 2H), 2.25 (s, 3H), 2.32 (dd, 1H), 2.41 (s, 6H), 2.50 (dd, 1H), 3.89 (m, 1H), 4.95 (dd, 1H), 5.92 (d, broad, 1H), 6.78 (dd, 1H), 6.90 (s, 2H), 7.05 (dt, 1H), 7.22 (dt, 1H), 7.41 (d, 1H), 7.59 (s, broad, 1H).

[0505] General Method for Preparing 2-[1-(mesitylsulfonyl)-3-oxo-1,2,3,4-tetrahydro-2-quinoxalinyl]acetamides Starting from Aliphatic Amines and the Compound of Example VI: 29

[0506] A solution of 0.07 mmol of the aliphatic primary or secondary amine, 40.4 mg (0.10 mmol) of 2-[1-(mesitylsulfonyl)-3-oxo-1,2,3,4-tetrahydro-2-quinoxalinyl]acetic acid (example VI), 15.8 mg (0.121 mmol) of 1-hydroxy-1H-benzotriazole and 200 mg of PS-carbodiimide (loading 0.94 mmol/g; from Argonaut) in 3 ml of dichloromethane is shaken at room temperature overnight. 200 mg of PS-trisamine (loading 3.85 mmol/g; from Argonaut) are added, and the mixture is shaken at room temperature for 6 hours. It is filtered through a silica gel cartridge (3 g) and washed with a 95:5 dichloromethane/methanol mixture. The mother liquor is mixed with 0.5 ml of a sat. sodium bicarbonate solution and shaken at RT for 30 min. It is filtered through an Extrelut/silica gel cartridge (1 g of each), and the solvent is distilled off in vacuo. The respective products are obtained and analyzed by LC/MS (Eluent:solution A=acetonitrile, solution B=water+0.6 g of HCl (30%)/l of water, Gradient: A/B 10:90 to A/B 90:10 within 4 min; Flow rate 0.6 ml/min; T=50° C.; Column: Kromasil RP-18, 2.1×150 mm).

[0507] Examples 2-106 listed in table 1 and 2 are obtained in accordance with this method. The optically active compounds in table 2 are prepared starting from dimethyl L-aspartate:

TABLE 1
Ex.				LC/MS
No.	Structure	Yield	LC-MS	method
2	30	99%	Rt = 4.48 min; MS (ESIpos): 484 [M+H]+	A
3	31	70%	Rt = 4.49 min; MS (ESIpos): 538 [M+H]+	A
4	32	99%	Rt = 4.25 min; MS (ESIpos): 470 [M+H]+	A
5	33	76%	Rt = 4.53 min; MS (ESIpos): 496 [M+H]+	A
6	34	75%	Rt = 4.21 min; MS (ESIpos): 458 [M+H]+	A
7	35	65%	Rt = 4.49 min; MS (ESIpos): 484 [M+H]+	A
8	36	99%	Rt = 4.48 min; MS (ESIpos): 484 [M+H]+	A
9	37	88%	Rt = 4.37 min; MS (ESIpos): 506 [M+H]+	A
10	38	86%	Rt = 4.37 min; MS (ESIpos): 506 [M+H]+	A
11	39	91%	Rt = 4.22 min; MS (ESIpos): 492 [M+H]+	A
12	40	84%	Rt = 4.08 min; MS (ESIpos): 508 [M+H]+	A
13	41	97%	Rt = 3.67 min; MS (ESIpos): 472 [M+H]+	A
14	42	88%	Rt = 4.17 min; MS (ESIpos): 496 [M+H]+	A
15	43	70%	Rt = 4.34 min; MS (ESIpos): 513 [M+H]+	A
16	44	87%	Rt = 4.41 min; MS (ESIpos): 506 [M+H]+	A
17	45	94%	Rt = 4.25 min; MS (ESIpos): 514 [M+H]+	A
18	46	88%	Rt = 4.07 min; MS (ESIpos): 456 [M+H]+	A
19	47	97%	Rt = 4.34 min; MS (ESIpos): 492 [M+H]+	A
20	48	85%	Rt = 4.18 min; MS (ESIpos): 496 [M+H]+	A
21	49	88%	Rt = 4.03 min; MS (ESIpos): 536 [M+H]+	A
22	50	99%	Rt = 4.17 min; MS (ESIpos): 496 [M+H]+	A
23	51	99%	Rt = 4.35 min; MS (ESIpos): 513 [M+H]+	A
24	52	99%	Rt = 4.09 min; MS (ESIpos): 482 [M+H]+	A
25	53	96%	Rt = 4.57 min; MS (ESIpos): 547 [M+H]+	A
26	54	91%	Rt = 4.06 min; MS (ESIpos): 484 [M+H]+	A
27	55	59%	Rt = 3.84 min; MS (ESIpos): 430 [M+H]+	A
28	56	84%	Rt = 3.93 min; MS (ESIpos): 442 [M+H]+	A
29	57	76%	Rt = 3.93 min; MS (ESIpos): 468 [M+H]+	A
30	58	71%	Rt = 3.82 min; MS (ESIpos): 430 [M+H]+	A
31	59	99%	Rt = 4.05 min; MS (ESIpos): 444 [M+H]+	A
32	60	66%	Rt = 2.91 min; MS (ESIpos): 539 [M+H]+	A
33	61	85%	Rt = 4.37 min; MS (ESIpos): 513 [M+H]+	A
34	62	99%	Rt = 4.03 min; MS (ESIpos): 522 [M+H]+	A
35	63	91%	Rt = 4.31 min; MS (ESIpos): 492 [M+H]+	A
36	64	85%	Rt = 4.48 min; MS (ESIpos): 546 [M+H]+	A
37	65	99%	Rt = 4.55 min; MS (ESIpos): 562 [M+H]+	A
38	66	84%	Rt = 3.79 min; MS (ESIpos): 474 [M+H]+	A
39	67	99%	Rt = 4.00 min; MS (ESIpos): 474 [M+H]+	A
40	68	86%	Rt = 3.89 min; MS (ESIpos): 442 [M+H]+	A
41	69	99%	Rt = 3.76 min; MS (ESIpos): 442 [M+H]+	A
42	70	85%	Rt = 3.66 min; MS (ESIpos): 428 [M+H]+	A
43	71	74%	Rt = 4.51 min; MS (ESIpos): 502 [M+H]+	A
44	72	73%	Rt = 4.26 min; MS (ESIpos): 476 [M+H]+	A
45	73	86%	Rt = 2.82 min; MS (ESIpos): 502 [M+H]+	B
46	74	40%	Rt = 2.72 min; MS (ESIpos): 488 [M+H]+	B
47	75	92%	Rt = 2.83 min; MS (ESIpos): 502 [M+H]+	B
48	76	88%	Rt = 2.78 min; MS (ESIpos): 502 [M+H]+	B
49	77	85%	Rt = 2.79 min; MS (ESIpos): 492 [M+H]+	B
50	78	86%	Rt = 2.87 min; MS (ESIpos): 518 [M+H]+	B
51	79	85%	Rt = 2.83 min; MS (ESIpos): 504 [M+H]+	B
52	80	90%	Rt = 2.88 min; MS (ESIpos): 518 [M+H]+	B

[0508]

TABLE 2
		MS	Rt		LC/MS
Ex. No.	Structure	[M+H]	[min]	Yield	method
53	81	464	4.6	75%	A
54	82	458	4	82%	A
55	83	444	4.4	quantitative	A
56	84	459	4.16	quantitative	A
57	85	546	4.46	92%	A
58	86	560	4.49	93%	A
59	87	522	4.07	quantitative	A
60	88	508	4.09	quantitative	A
61	89	479	2.97	quantitative	A
62	90	479	2.66	84%	A
63	91	446	3.47	quantitative	A
64	92	510	4.23	82%	A
65	93	492	4.21	quantitative	A
66	94	614	4.68	quantitative	A
67	95	546	4.36	quantitative	A
68	96	510	4.17	89%	A
69	97	520	4.47	quantitative	A
70	98	501	2.67	quantitative	A
71	99	499	2.76	64%	A
72	100	456	3.98	99%	A
73	101	471	2.63	60%	A
74	102	456	3.91	27%	A
75	103	558	4.59	71%	A
76	104	568	4.81	73%	A
77	105	602	4.96	86%	A
78	106	547	4.62	99%	A
79	107	569	4.46	88%	A
80	108	551	4.31	78%	A
81	109	563	4.15	78%	A
82	110	579	4.57	75%	A
83	111	561	4.39	90%	A
84	112	547	4.27	79%	A
85	113	458	4.15	24%	A
86	114	566	4.02	71%	A
87	115	528	4	65%	A
88	116	484	4.1	37%	A
89	117	493	2.91	96%	A
90	118	493	2.8	70%	A
91	119	560	4.76	84%	A
92	120	522	4.18	96%	A
93	121	482	4.02	71%	A
94	122	515	2.71	78%	A
95	123	547	2.93	69%	A
96	124	486	3.87	69%	A
97	125	440	3.67	70%	A
98	126	460	3.67	44%	A
99	127	499	3.32	44%	A
100	128	470	4.2	46%	A
101	129	507	2.9	98%	A
102	130	561	4.82	82%	A
103	131	567	4.59	62%	A
104	132	563	4.25	67%	A
105	133	601	4.92	75%	A
106	134	581	3.12	99%	A

[0509] General Method for Preparing 2-[1-(mesitylsulfonyl)-3-oxo-1,2,3,4-tetrahydro-2-quinoxalinyl]acetamides Starting from Aromatic Amines and the Compound of Example VI: 135

[0510] A solution of 0.08 mmol of the aromatic primary or secondary amine, 25.3 mg (0.07 mmol) of 2-[1-(mesitylsulfonyl)-3-oxo-1,2,3,4-tetrahydro-2-quinoxalinyl]acetic acid (example VI), 29.7 mg (0.08 mmol) of [O-(7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium]hexafluorophosphate (HATU) and 16.8 mg (0.13 mmol) of N,N-diisopropylethylamine in 3 ml of DMF is shaken at room temperature overnight. It is filtered and the solvent is distilled off. The residue is filtered through a silica gel cartridge and washed with a 90:10 dichloromethane/methanol solvent mixture. It is evaporated and the crude product is purified by a preparative RP-HPLC (Kromasil 100 C18, 5 μm; 50×20 mm; Gradient: acetonitrile/water 15:85 to 90:10, room temperature).

[0511] Examples 107-131 listed in table 3 are obtained in accordance with this method:

TABLE 3
				LC/MS
Example	Structure	Yield	LC-MS	method
107	136	31%	Rt = 4.41 min; MS (ESIpos): 538 [M + H]+	A
108	137	20%	Rt = 4.58 min; MS (ESIpos): 518 [M + H]+	A
109	138	40%	Rt = 4.41 min; MS (ESIpos): 492 [M + H]+	A
110	139	34%	Rt = 4.24 min; MS (ESIpos): 478 [M + H]+	A
111	140	36%	Rt = 4.16 min; MS (ESIpos): 524 [M + H]+	A
112	141	5%	Rt = 4.71 min; MS (ESIpos): 533 [M + H]+	A
113	142	46%	Rt = 4.51 min; MS (ESIpos): 492 [M + H]+	A
114	143	34%	Rt = 5.23 min; MS (ESIpos): 560 [M + H]+	A
115	144	7%	Rt = 4.19 min; MS (ESIpos): 522 [M + H]+	A
116	145	58%	Rt = 4.74 min; MS (ESIpos): 506 [M + H]+	A
117	146	14%	Rt = 4.63 min; MS (ESIpos): 532 [M + H]+	A
118	147	6%	Rt = 4.55 min; MS (ESIpos): 492 [M + H]+	A
119	148	14%	Rt = 4.69 min; MS (ESIpos): 533 [M + H]+	A
120	149	68%	Rt = 4.71 min; MS (ESIpos): 556 [M + H]+	A
121	150	63%	Rt = 4.21 min; MS (ESIpos): 494 [M + H]+	A
122	151	69%	Rt = 4.76 min; MS (ESIpos): 556 [M + H]+	A
123	152	21%	Rt = 4.67 min; MS (ESIpos): 548 [M + H]+	A
124	153	10%	Rt = 4.40 min; MS (ESIpos): 536 [M + H]+	A
125	154	31%	Rt = 4.53 min; MS (ESIpos): 499 [M + H]+	A
126	155	25%	Rt = 4.77 min; MS (ESIpos): 533 [M + H]+	A
127	156	11%	Rt = 4.91 min; MS (ESIpos): 533 [M + H]+	A
128	157	43%	Rt = 2.73 min; MS (ESIpos): 514 [M + H]+	B
129	158	87%	Rt = 2.D2978 min; MS (ESIpos): 510 [M + H]+	B
130	159	68%	Rt = 2.80 min; MS (ESIpos): 534 [M + H]+	B
131	160	29%	Rt = 2.65 min; MS (ESIpos): 530 [M + H]+	B

[0512] General Method for the Sulfonylation of N-benzyl-2-(3-oxo-1,2,3,4-tetrehydro-2-quinoxalinyl)acetamide (Example I): 161

[0513] A solution of 30.7 mg (0.10 mmol) of N-benzyl-2-(3-oxo-1,2,3,4-tetrahydro-2-quinoxalinyl)acetamide (example I) and 0.21 inmol of the sulfonyl chloride in 3 ml of pyridine is stirred at 80° C. in an argon atmosphere overnight. The solvent is distilled off in vacuo, and the residue is purified by a preparative RP-HPLC (Kromasil 100 C18, 5 μm; 50×20 mm; Gradient: acetonitrile/water 15:85 to 90:10, room temperature).

[0514] Examples 132-159 listed in table 4 are obtained in accordance with this method:

TABLE 4
				LC/MS
Example	Structure	Yield	LC-MS	method
132	162	9%	Rt = 4.54 min; MS (ESIpos): 597 [M + H]+	A
133	163	3%	Rt = 4.14 min; MS (ESIpos): 518 [M + H]+	A
134	164	11%	Rt = 3.90 min; MS (ESIpos): 464 [M + H]+	A
135	165	2%	Rt = 4.15 min; MS (ESIpos): 519 [M + H]+	A
136	166	3%	Rt = 4.05 min; MS (ESIpos): 500 [M + H]+	A
137	167	23%	Rt = 3.91 min; MS (ESIpos): 486 [M + H]+	A
138	168	5%	Rt = 3.74 min; MS (ESIpos): 450 [M + H]+	A
139	169	2%	Rt = 4.11 min; MS (ESIpos): 490 [M + H]+	A
140	170	19%	Rt = 4.24 min; MS (ESIpos): 492 [M + H]+	A
141	171	14%	Rt = 3.96 min; MS (ESIpos): 488 [M + H]+	A
142	172	6%	Rt = 3.66 min; MS (ESIpos): 466 [M + H]+	A
143	173	9%	Rt = 3.02 min; MS (ESIpos): 440 [M + H]+	A
144	174	10%	Rt = 3.75 min; MS (ESIpos): 450 [M + H]+	A
145	175	14%	Rt = 3.62 min; MS (ESIpos): 472 [M + H]+	A
146	176	2%	Rt = 3.87 min; MS (ESIpos): 476 [M + H]+	A
147	177	14%	Rt = 3.87 min; MS (ESIpos): 470 [M + H]+	A
148	178	43%	Rt = 3.59 min; MS (ESIpos): 436 [M + H]+	A
149	179	4%	Rt = 3.60 min; MS (ESIpos): 454 [M + H]+	A
150	180	3%	Rt = 3.64 min; MS (ESIpos): 455 [M + H]+	A
151	181	27%	Rt = 3.77 min; MS (ESIpos): 509 [M + H]+	A
152	182	21%	Rt = 3.74 min; MS (ESIpos): 450 [M + H]+	A
153	183	31%	Rt = 3.57 min; MS (ESIpos): 517 [M + H]+	A
154	184	42%	Rt = 2.71 min; MS (ESIpos): 506 [M + H]+	B
155	185	12%	Rt = 4.4 min; MS (ESIpos): 566 [M + H]+	A
156	186	7%	Rt = 4.01 min; MS (ESIpos): 518 [M + H]+	A
157	187	56%	Rt = 3.9 min; MS (ESIpos): 524 [M + H]+	A
158	188	7%	Rt = 4.13 min; MS (ESIpos): 532 [M + H]+	A
159	189	5%	Rt = 4.38 min; MS (ESIpos): 514 [M + H]+	A

[0515] General Method for the Sulfonylation of N-cycloheptyl-2-(oxo-1,2,3,4-tetrahydro-2-quinoxalinyl)acetamide (example VIII): 190

[0516] A solution of 100 mg (0.33 mmol) of N-cycloheptyl-2-(oxo-1,2,3,4-tetrahydro-2-quinoxalinyl)acetamide and 0.4 mmol of the sulfonyl chloride in 59 μl of pyridine and 3 ml of acetonitrile is stirred at 60° C. in an argon atmosphere overnight. The solvent is distilled off in vacuo, and the residue is purified by a preparative RP-HPLC (Kromasil 100 C18, 5 μm; 50×20 mm; Gradient: acetonitrile/water 15:85 to 90:10, room temperature).

[0517] Examples 160-180 listed in table 5 are obtained in accordance with this method:

TABLE 5
				LC/MS
Example	Structure	Yield	LC-MS	method
160	191	38%	Rt = 2.92 min; MS (ESIpos): 512 [M + H]+	B
161	192	47%	Rt = 2.56 min; MS (ESIpos): 506 [M + H]+	B
162	193	31%	Rt = 2.62 min; MS (ESIpos): 506 [M + H]+	B
163	194	59%	Rt = 2.69 min; MS (ESIpos): 470 [M + H]+	B
164	195	48%	Rt = 2.67 min; MS (ESIpos): 550 [M + H]+	B
165	196	24%	Rt = 2.60 min; MS (ESIpos): 520 [M + H]+	B
166	197	37%	Rt = 2.83 min; MS (ESIpos): 504 [M + H]+	B
167	198	50%	Rt = 2.53 min; MS (ESIpos): 472 [M + H]+	B
168	199	34%	Rt = 2.72 min; MS (ESIpos): 534 [M + H]+	B
169	200	6%	Rt = 2.79 min; MS (ESIpos): 604 [M + H]+	B
170	201	12%	Rt = 4.9 min; MS (ESIpos): 603 [M + H]+	A
171	202	9%	Rt = 4.D185 min; MS (ESIpos): 525 [M + H]+	A
172	203	14%	Rt = 4.6 min; MS (ESIpos): 579 [M + H]+	A
173	204	17%	Rt = 4.5 min; MS (ESIpos): 545 [M + H]+	A
174	205	15%	Rt = 4.2 min; MS (ESIpos): 511 [M + H]+	A
175	206	9%	Rt = 3.8 min; MS (ESIpos): 467 [M + H]+	A
176	207	12%	Rt = 4.5 min; MS (ESIpos): 524 [M + H]+	A
177	208	6%	Rt = 4.3 min; MS (ESIpos): 511 [M + H]+	A
178	209	17%	Rt = 4.6 min; MS (ESIpos): 545 [M + H]+	A
179	210	13%	Rt = 4.7 min; MS (ESIpos): 578 [M + H]+	A
180	211	26%	Rt = 2.78 min; MS (ESIpos): 524 [M + H]+	B

BEISPIEL 181

N-Phenylmethyl-2-[1-(mesitylsulfonyl)-3-oxo-1,2,3,4-tetrahydro-2-quinoxalinyl]acetamide

[0518] 212

[0519] 1.02 g (3.44 mmol) of N-phenylmethyl-2-(3-oxo-1,2,3,4-tetrahydro-2-quinoxalinyl)acetamide (example I) are suspended in about 10 ml of acetonitrile, and 3.80 g (17.4 mmol) of 2,4,6-trimethylphenylsulfonyl chloride and 523 mg (3.78 mmol) of potassium carbonate are added. The mixture is heated to reflux under an argon atmosphere for 3 hours. The mixture is then allowed to cool, and the contents of the flask are poured into water. The resulting brown solid is removed and triturated with diethyl ether. The beige crude product is purified fuirther by chromatography on silica gel (mobile phase: 1:1 dichloromethane/diethyl ether). This results in 770 mg (47%) of the target compound as a pale yellowish solid.

[0520] 1 H-NMR (200 MHz, DMSO-d6): δ=2.07-2.41 (m, 11H), 4.01-4.35 (ABX system, AB part, 2H), 4.81 (dd, 1H), 6.89-7.39 (m, 11H), 8.35 (t, 1H), 10.65 (s, 1H).

[0521] MS (DCI, NH3): m/z=495 [M+NH4]+, 478 [M+H]+.

EXAMPLE 182

N-(2-Methoxyphenyl)-2-[1-(mesitylsulfonyl)-3-oxo-1,2,3,4-tetrahydro-2-quinoxalinyl]acetamide

[0522] 213

[0523] This compound is obtained in analogy to the method of example 86 from 642 mg (2.06 mmol) of N-(2-methoxyphenyl)-2-(3-oxo-1,2,3,4-tetrahydro-2-quinoxalinyl)acetamide (example II) and 2.25 g (10.3 mmol) of 2,4,6-trimethylphenylsulfonyl chloride by heating to reflux for 2 hours and stirring the initially obtained brownish red solid with acetone.

[0524] Yield: 804 mg (79%) of a colorless solid.

[0525] 1 H-NMR (200 MHz, DMSO-d6): δ=2.25 (s, 3H), 2.32 (s, 6H), 2.56 (d, 2H), 3.76 (s, 3H), 4.82 (t, 1H), 6.70-7.38 (m, 9H), 7.91 (d, 1H), 9.13 (s, 1H), 10.67 (s, 1H).

[0526] MS (DCI, NH3): m/z=511 [M+NH4]+, 494 [M+H]+.

EXAMPLE 183 AND EXAMPLE 184

2S-N-Cycloheptyl-2-[1-(mesitylsulfonyl)-3-oxo-1,2,3,4-tetrahydro-2-quinoxalinyl]acetamide and 2R-N-cycloheptyl-2-[1-(mesitylsulfonyl)-3-oxo-1,2,3,4-tetrahydro-2-quinoxalinyl]acetamide

[0527] 214

[0528] 4 g of N-cycloheptyl-2RS-[1-(mesitylsulfonyl)-3-oxo-1,2,3,4-tetrahydro-2-quinoxalinyl]acetamide (example 1) are separated into the enantiomers by means of a chiral HPLC.

[0529] Description of method:

Sample preparation: 4 g dissolved in 750 ml of ethyl acetate
Sample loading:     400 mg every 36 min
Flow rate:          40 ml/min
Wave length:        254 nM
Solvent:            ethyl acetate
Packing material:   6784 (600*30); LNW 2951; N-MA-L-leu-2,4-
                    dimethylpentyl-amide

[0530] The following are obtained:

[0531] S-N-Cycloheptyl-2-[1-(mesitylsulfonyl)-3-oxo-1,2,3,4-tetrahydro-2-quinoxalinyl]acetamide: 1.95 g (Rt=20.292 min).

[0532] Specific rotation [α]20D=−88.6° (c=0.485; MeOH).

[0533] and R-N-cycloheptyl-2-[1-(mesitylsulfonyl)-3-oxo-1,2,3,4-tetrahydro-2-quinoxalinyl]acetamide: 1.75 g (Rt=32.925 min).

[0534] Specific rotation [α]20D=+95.8° (c=0.514; MeOH).

[0535] (The concentration c stated in connection with the specific rotation is defined as the amount of substance (in g) per 100 ml of solution. Path length: 100 mm).

TABLE 6
		MW	Yield		LC/MS
Example	Structure	[g/mol]	%	LC-MS/MS	method
185	215	570.85	51	MS(ESIpos): m/z = 570 (M + H) Rt = 2.84 min	B
186	216	570.85	42	MS(ESIpos): m/z = 570 (M + H) Rt = 2.89 min	B
187	217	554.40	66	MS(ESIpos): m/z = 554 (M + H) Rt = 2.78 min	B
188	218	554.40	16	MS(ESIpos): m/z = 554 (M + H) Rt = 2.83 min	B
189	219	550.44	37	MS(ESIpos): m/z = 550 (M + H) Rt = 2.91 min	B
190	220	566.89	44	MS(ESIpos): m/z = 566 (M + H) Rt = 3.02 min	B
191	221	566.89	12	MS(ESIpos): m/z = 566 (M + H) Rt = 3.07 min	B
192	222	566.43	60	MS(DCI): m/z = 583 (M + NH4)
193	223	495.57	42	MS(ESIpos): m/z = 496 (M + H) Rt = 2.71 min	B
194	224	513.56	44	MS(ESIpos): m/z = 514 (M + H) Rt = 2.72 min	B
195	225	507.61	38	MS(ESIpos): m/z = 508 (M + H) Rt = 2.63 min	B
196	226	499.59	31	MS(ESIpos): m/z = 500 (M + H) Rt = 4.30 min	A
197	227	507.61	18	MS(ESIpos): m/z = 508 (M + H) Rt = 4.47 min	A
198	228	536.41	13	MS(ESIpos): m/z = 536 (M + H) Rt = 4.52 min	A
199	229	512.03	29	MS(ESIpos): m/z = 512 (M + H) Rt = 2.84 min	B
200	230	511.57	34	MS(ESIpos): m/z = 512 (M + H) Rt = 2.75 min	B
201	231	491.61	26	MS(ESIpos): m/z = 492 (M + H) Rt = 2.72 min	B
202	232	512.03	27	MS(ESIpos): m/z = 512 (M + H) Rt = 2.77 min	B
203	233	522.38	20	MS(ESIpos): m/z = 522 (M + H) Rt = 4.34 min	A
204	234	521.63	20	MS(ESIpos): m/z = 522 (M + H) Rt = 2.85 min	B
205	235	505.64	24	MS(ESIpos): m/z = 506 (M + H) Rt = 4.59 min	A
206	236	556.48	25	MS(ESIpos): m/z = 556 (M + H) Rt = 2.82 min	B
207	237	569.68	6	MS(ESIpos): m/z = 570 (M + H) Rt = 2.91 min	B
208	238	574.82	31	MS(DCI): m/z = 593 (M + NH4)
209	239	576.50	4	MS(ESIpos): m/z = 576 (M + H) Rt = 2.86 min	B
210	240	506.56	68	MS(ESIpos): m/z = 507 (M + H) Rt = 4.43 min	A
211	241	515.99	2	MS(ESIpos): m/z = 516 (M + H) Rt = 4.54 min	A
212	242	536.41	7	MS(ESIpos): m/z = 536 (M + H) Rt = 4.43 min	A
213	243	561.58	28	MS(ESIpos): m/z = 562 (M + H) Rt = 4.70 min	A
214	244	545.58	53	MS(ESIpos): m/z = 546 (M + H) Rt = 4.63 min	A
215	245	545.58	12	MS(ESIpos): m/z = 546 (M + H) Rt = 4.66 min	A
216	246	532.45	22	MS(ESIneg): m/z = 530 (M − H) Rt = 4.71 min	A
217	247	498.00	45	MS(ESIpos): m/z = 498 (M + H)
218	248	512.03	71	MS(ESIneg): m/z = 510 (M − H) Rt = 4.57 min	A
219	249	542.05	89	MS(ESIpos): m/z = 542 (M + H) Rt = 4.74 min	A
220	250	515.99	37	MS(ESIpos): m/z = 516 (M + H) Rt = 4.44 min	A
221	251	531.99	50	MS(ESIneg): m/z = 530 (M − H) Rt = 4.56 min	A
222	252	532.45	8	MS(ESIpos): m/z = 532 (M + H) Rt = 4.72 min	A
223	253	515.99	29	MS(ESIpos): m/z = 516 (M + H) Rt = 4.53 min	A
224	254	536.41	22	MS(ESIpos): m/z = 536 (M + H) Rt = 4.58 min	A
225	255	560.07	76	MS(ESIpos): m/z = 560 (M + H) Rt = 4.91 min	A
226	256	607.73	7	MS(ESIpos): m/z = 606 (M + H) Rt = 5.00 min	A
227	257	535.52	42	MS(ESIpos): m/z = 536 (M + H)
228	258	571.93	36	MS(DCI): m/z = 589 (M + NH4)
229	259	607.73	4	MS(ESIpos): m/z = 605 (M + H)
230	260	501.96	66	MS(ESIpos): m/z = 502 (M + H)
231	261	536.41	46	MS(ESIpos): m/z = 536 (M + H)
232	262	535.52	28	MS(ESIpos): m/z = 536 (M + H)
233	263	522.38	82	MS(ESIpos): m/z = 522 (M + H)
234	264	501.96	36	MS(ESIpos): m/z = 502 (M + H)
235	265	590.38	63	MS(ESIpos): m/z = 590 (M + H)
236	266	519.61	42.85	LCMS: Rt =2.87 min MS(ESIpos): m/z = 520 (M + H)	B
237	267	463.56	47.4	LCMS: Rt =3.92 min MS(ESIpos): m/z = 464 (M + H)	A
238	268	546.47	46.5	LCMS: Rt =4.71 min MS(ESIpos): m/z = 448 (M + H)	A
239	269	526.05	34.9	LCMS: Rt =4.58 min MS(ESIpos): m/z = 526 (M + H)	A
240	270	501.62	88.1	LCMS: Rt =4.61 min MS(ESIpos): m/z = 502 (M + H)	A
241	271	475.48	91	LCMS: Rt =4.37 min MS(ESIpos): m/z = 476 (M + H)	A
242	272	555.59	73	LCMS: Rt =4.59 min MS(ESIpos): m/z = 556 (M + H)	A
243	273	542.00	48	LCMS: Rt =4.60 min MS(ESIpos): m/z = 542 (M + H)	A
244	274	560.45	27.1	LCMS: Rt =5.07 min MS(ESIpos): m/z = 560 (M + H)	B
245	275	540.03	56	LCMS: Rt =2.95 min MS(ESIpos): m/z = 540 (M + H)	B
246	276	547.66	43	LCMS: Rt =3.01 min MS(ESIpos): m/z = 548 (M + H)	B
247	277	546.42	16.05	LCMS: Rt =4.66 min MS(ESIpos): m/z = 546 (M + H)	A
248	278	459.54	65.2	LCMS: Rt =4.00 min MS(ESIpos): m/z = 460 (M + H)	A
249	279	467.52	62	LCMS: Rt =4.00 min MS(ESIpos): m/z = 468 (M + H)	A
250	280	515.65	85	LCMS: Rt =4.70 min MS(ESIpos): m/z = 416 (M + H)	A
251	281	495.57	82	LCMS: Rt =4.50 min MS(ESIpos): m/z = 496 (M + H)	A
252	282	523.63	54.4	LCMS: Rt =4.60 min MS(ESIpos): m/z = 524 (M + H)	A
253	283	536.41	47.3	LCMS: Rt =4.74 min MS(ESIpos): m/z = 537 (M + H)	A
254	284	537.94	20.5	LCMS: Rt =4.71 min MS(ESIpos): m/z = 538 (M + H)	A
255	285	554.40	41.3	LCMS: Rt =4.90 min MS(ESIpos): m/z = 554 (M + H)	A
256	286	554.40	60.5	LCMS: Rt =4.70 min MS(ESIpos): m/z = 554 (M + H)	A
257	287	552.86	91.9	LCMS: Rt =4.90 min MS(ESIpos): m/z = 554 (M + H)	A
258	288	597.32	59.9	LCMS: Rt =5.0 min MS(ESIpos): m/z = 598 (M + H)	A
259	289	550.44	53	LCMS: Rt =4.75 min MS(ESIpos): m/z = 550 (M + H)	A
260	290	536.41	60.34	LCMS: Rt =4.80 min MS(ESIpos): m/z = 538 (M + H)	A
261	291	550.44	41.5	LCMS: Rt =4.80 min MS(ESIpos): m/z = 550 (M + H)	A
262	292	533.98	45.4	LCMS: Rt =4.60 min MS(ESIpos): m/z = 534 (M + H)	A
263	293	537.94	28	LCMS: Rt =4.70 min MS(ESIpos): m/z = 538 (M + H)	A
264	294	537.94	50.6	LCMS: Rt =4.54 min MS(ESIpos): m/z = 538,2 (M + H)	A
265	295	552.98	26	LCMS: Rt =4.60 min MS(ESIpos): m/z = 538 (M + H)	A
266	296	515.99	53	LCMS: Rt =5.34 min MS(ESIpos): m/z = 538 (M + H)	A
267	297	536.41	15	LCMS: Rt =4.28 min MS(ESIpos): m/z = 536 (M + H)	A
268	298	495.57	56.1	LCMS: Rt =5.04 min MS(ESIpos): m/z = 496 (M + H)	A
269	299	515.99	79.8	LCMS: Rt =2.75 min MS(ESIpos): m/z = 516 (M + H)	B
270	300	533.98	76	LCMS: Rt =2.76 min MS(ESIpos): m/z = 534 (M + H)	B
271	301	530.02	74.4	LCMS: Rt =2.89 min MS(ESIpos): m/z = 530 (M + H)	B
272	302	516.98	73	LCMS: Rt =2.19 min MS(ESIpos): m/z = 517 (M + H)	B
273	303	550.44	73.1	LCMS: Rt =2.92 min MS(ESIpos): m/z = 550 (M + H)	B
274	304	515.99	100	LCMS: Rt =2.76 min MS(ESIpos): m/z = 516 (M + H)	B
275	305	533.98	77.3	LCMS: Rt =2.78 min MS(ESIpos): m/z = 534 (M + H)	B
276	306	530.02	78.3	LCMS: Rt =2.90 min MS(ESIpos): m/z = 530 (M + H)	B
277	307	530.02	72.1	LCMS: Rt =2.78 min MS(ESIpos): m/z = 530 (M + H)	B
278	308	516.98	67	LCMS: Rt =2.00 min MS(ESIpos): m/z = 517 (M + H)	B
279	309	516.98	71	LCMS: Rt =1.95 min MS(ESIpos): m/z = 517 (M + H)	B
280	310	550.44	77.2	LCMS: Rt =2.76 min MS(ESIpos): m/z = 550 (M + H)	B
281	311	550.44	69.4	LCMS: Rt =2.79 min MS(ESIpos): m/z = 550 (M + H)	B
282	312	550.44	71.5	LCMS: Rt =4.58 min MS(ESIpos): m/z = 550 (M + H)	A
283	313	551.97	73.1	LCMS: Rt =4.46 min MS(ESIpos): m/z = 551 (M + H)	A
284	314	568.43	64.2	LCMS: Rt =4.63 min MS(ESIpos): m/z = 568 (M + H)	A
285	315	584.88	80.04	LCMS: Rt =4.84 min MS(ESIpos): m/z = 586 (M + H)	A
286	316	599.99	73.16	LCMS: Rt =4.76 min MS(ESIpos): m/z = 600 (M + H)	A
287	317	566.89	70.81	LCMS: Rt =4.74 min MS(ESIpos): m/z = 566 (M + H)	A
288	318	533.43	44.12	LCMS: Rt =3.26 min MS(ESIpos): m/z = 533 (M + H)	A
289	319	498.00	93.8	MS(ESIpos): m/z = 498 (M + H) HPLC: Rt =4.74 min	C
290	320	566.00	94	MS(ESIpos): m/z = 566 (M + H) HPLC: Rt =4.98 min	C
291	321	566.00	96	MS(ESIpos): m/z = 566 (M + H) HPLC: Rt =4.97 min	C
292	322	566.00	95	MS(ESIpos): m/z = 566 (M + H) HPLC: Rt =4.98 min	C
293	323	526.05	94	MS(ESIpos): m/z = 526 (M + H) HPLC: Rt =4.97 min	C
294	324	530.02	95	MS(ESIpos): m/z = 530 (M + H) HPLC: Rt =4.85 min	C
295	325	533.98	94	MS(ESIpos): m/z = 534 (M + H) HPLC: Rt =4.77 min	C
296	326	566.89	93	MS(ESIpos): m/z = 566 (M + H) HPLC: Rt =5.12 min	C
297	327	542.01	90	MS(ESIpos): m/z = 542 (M + H) HPLC: Rt =4.64 min	C
298	328	504.03	91	MS(ESIpos): m/z = 504 (M + H) HPLC: Rt =4.66 min	C
299	329	554.09	93	MS(ESIpos): m/z = 554 (M + H) HPLC: Rt =4.95 min	C
300	330	498.99	95	MS(ESIpos): m/z = 499 (M + H) HPLC: Rt =4.09 min	C
301	331	498.99	92	MS(ESIpos): m/z = 499 (M + H) HPLC: Rt =4.03 min	C
302	332	498.99	93	MS(ESIpos): m/z = 499 (M + H) HPLC: Rt =4.09 min	C
303	333	513.02	94	MS(ESIpos): m/z = 513 (M + H) HPLC: Rt =4.01 min	C
304	334	513.02	89	MS(ESIpos): m/z = 513 (M + H) HPLC: Rt =4.05 min	C
305	335	513.02	87	MS(ESIpos): m/z = 513 (M + H) HPLC: Rt =4.04 min	C
306	336	533.43	92	MS(ESIpos): m/z = 533 (M + H) HPLC: Rt =4.52 min	C
307	337	560.03	94	MS(ESIpos): m/z = 560 (M + H) HPLC: Rt =4.58 min	C
308	338	501.99	94	MS(ESIpos): m/z = 502 (M + H) HPLC: Rt =4.68 min	C
309	339	517.01	97	MS(ESIpos): m/z = 517 (M + H) HPLC: Rt =4.07 min	C
310	340	558.10	48	MS(ESIpos): m/z = 558 (M + H) HPLC: Rt =4.23 min	C

Claims

1. A compound of the formula (I) or (Ia),

2. The compound as claimed in claim 1, where A is (C1-C6)-alkanediyl, E is a bond or (C1-C6)-alkanediyl, Y is CO, R1, R2, R3 and R4 are identical or different and are hydrogen, halogen, trifluoromethyl, trifluoromethoxy, hydroxyl, nitro, cyano, amino, (C1-C6)-alkyl, (C1-C6)-alkoxy, (C1-C6)-alkylthio, mono- or di-(C1-C6)-alkylamino, (C1-C6)-acyl, (C1-C6)-acyloxy, (C1-C6)-acylamino, (C1-C6)-alkoxycarbonyl, mono- or di-(C1-C6)-alkylaminocarbonyl, carbamoyl or carboxyl, R5 is (C6-C10)-aryl or 5- to 10-membered heteroaryl, where aryl and heteroaryl are optionally substituted identically or differently by radicals selected from the group of halogen, trifluoromethyl, trifluoromethoxy, hydroxyl, nitro, cyano, amino, (C1-C6)-alkyl, (C1-C6)-alkoxy, phenoxy, (C1-C6)-alkylthio, mono- or di-(C1-C6)-alkylamino, (C1-C6)-acyl, (C1-C6)-acyloxy, (C1-C6)-acylamino, (C1-C6)-alkoxycarbonyl, mono- or di-(C1-C6)-alkylaminocarbonyl, carbamoyl, carboxyl, phenyl, 5- to 6-membered heteroaryl, propane-1,3-diyl, butane-1,4-diyl, 1,3-dioxapropane-1,3-diyl or 1,4-dioxabutane-1,4-diyl, in which phenoxy, phenyl and 5- to 6-membered heteroaryl are in turn optionally substituted identically or differently by trifluoromethyl, (C1-C6)-alkyl, (C1-C6)-alkoxy or halogen, R6 and R7 are identical or different and are hydrogen, (C6-C10)-aryl, 5- to 10-membered heteroaryl, 3- to 12-membered carbocyclyl, 4- to 12-membered heterocyclyl, or are (C1-C10)-alkyl which is optionally substituted by halogen or a radical selected from the group of (C1-C6)-alkoxy, (C6-C10)-aryl, 5- to 10-membered heteroaryl, 3- to 12-membered carbocyclyl and 4- to 12-membered heterocyclyl, where aryl, heteroaryl, heterocyclyl and carbocyclyl are optionally substituted identically or differently by radicals selected from the group of halogen, trifluoromethyl, trifluoromethoxy, hydroxyl, nitro, cyano, amino, (C1-C6)-alkyl, (C3-C8)-cycloalkyl, 5- to 7-membered heterocyclyl, (C1-C6)-alkoxy, phenoxy, (C1-C6)-alkylthio, mono- or di-(C1-C6)-alkylamino, (C1-C6)-acyl, (C1-C6)-acyloxy, (C1-C6)-acylamino, (C1-C6)-alkoxycarbonyl, mono- or di-(C1-C6)-alkylaminocarbonyl, carbamoyl, carboxyl, phenyl, 5- to 6-membered heteroaryl, propane-1,3-diyl, butane-1,4-diyl, 1,3-dioxapropane-1,3-diyl or 1,4-dioxabutane-1,4-diyl, or R6 and R7 together with the nitrogen atom form a 4- to 12-membered heterocyclyl radical which is bonded via nitrogen and which is optionally substituted identically or differently by radicals selected from the group of halogen, trifluoromethyl, trifluoromethoxy, hydroxyl, nitro, cyano, amino, (C1-C6)-alkyl, (C1-C6)-alkoxy, mono- or di-(C1-C6)-alkylamino, (C1-C6)-acyloxy, (C1-C6)-acyl, (C1-C6)-acylamino, (C1-C6)-alkoxycarbonyl, mono- or di-(C1-C6)-alkylaminocarbonyl, carbamoyl, carboxyl, (C3-C8)-cycloalkyl and phenyl, where alkyl, cycloalkyl and phenyl in turn are optionally substituted identically or differently by one to three radicals selected from the group of halogen, phenyl, (C1-C6)-alkyl, (C1-C6)-alkoxy and (C1-C6)-alkylthio, in which phenyl in turn is optionally substituted identically or differently by radicals selected from the group of halogen or methyl, R8 is hydrogen, R9 is hydrogen, and the salts, hydrates and/or solvates thereof, with the exception of 2-[3-oxo-1-(phenylsulfonyl)-1,2,3,4-tetrahydro-2-quinoxalinyl]-N-phenylacetamide.

3. The compound as claimed in claim 1, where A is methylene, E is a bond, Y is CO, R1, R2, R3 and R4are identical or different and are hydrogen or halogen, R5 is phenyl which is optionally substituted identically or differently by one to three radicals selected from the group of methyl, isopropyl, halogen, trifluoromethyl and trifluoromethoxy, R6 and R7 are identical or different and are hydrogen, (C1-C6)-alkyl, phenyl or 5- to 8-membered carbocyclyl, where R6 and R7 are not both hydrogen, and where carbocyclyl and phenyl is optionally substituted identically or differently by radicals selected from the group of halogen, trifluoromethyl, trifluoromethoxy, methyl and methoxy, R8 is hydrogen, R9 is hydrogen, and the salts, hydrates and/or solvates thereof, with the exception of 2-[3-oxo-1-(phenylsulfonyl)-1,2,3,4-tetrahydro-2quinoxalinyl]-N-phenylacetamide.

4. A process for preparing compounds of the formula (I) as claimed in claim 1, wherein [A] compounds of the general formula (II) or (IIa), 342in which A, E, Y, R1, R2, R3, R4, R5, R8 and R9 have the meaning indicated in claim 1, and X1 is halogen or hydroxyl, are reacted with compounds of the general formula (III) 343in which R6 and R7 have the meaning indicated in claim 1, or the salts thereof, in inert solvents, where appropriate in the presence of a base and where appropriate in the presence of condensing agents, or [C] compounds of the general formula (V), 344in which A, Y, R1, R2, R3, R4, R6, R7 and R8 have the meaning indicated in claim 1, are reacted with compounds of the general formula (VI) 345in which E and R5 have the meaning indicated in claim 1, and X3 is halogen, in inert solvents, where appropriate in the presence of a base.

5. A compound of the formula (V)

6. (Cancelled).

7. A pharmaceutical composition comprising one or more of the compounds as claimed in claim 1 mixed together with one or more pharmaceutically suitable, essentially nontoxic carrier or excipient.

8. A method for the treatment and/or prophylaxis of states of pain comprising administering to a subject in need thereof an effective amount of one or more compounds of claim 1.

9. (Cancelled).